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-Catenin is important in liver homeostasis as a part of Wnt signaling and adherens junctions 
(AJs); however, aberrant -catenin activation is observed in a subset of hepatocellular 
carcinomas (HCC). Since therapeutic targeting of -catenin in HCC is inevitable, it is important 
to investigate the implications of such interventions on AJs. We address this important issue both 
in vivo and in vitro. We observed that hepatocyte-specific -catenin knockout (KO) mice have 
no noticeable adhesive defects. We identified an increase in -catenin at AJs in KO livers. We 
further observed that -catenin was unable to translocate to the nucleus in absence of -catenin 
after partial hepatectomy in KO mice. Since -catenin is a desmosomal protein, we next 
investigated if -catenin changes in KOs were at the expense of desmosomes. We did not 
observe any differences on desmosomal structure or composition in KO livers. Similarly, as 
some tight junction components are -catenin target genes, we observed only minor changes in 
tight junctions, such that the function of the junctions was not affected in vivo. To further 
determine the role and regulation of -catenin in absence of -catenin we established an in vitro 
model. Hep3B human HCC cells transfected with siRNA to -catenin led to -catenin increase. 
Using this model we showed -catenin was unable to rescue decreased Wnt reporter activity. 
Scratch-wound assays showed - and -catenin single knockdowns did not affect cell migration, 
but double knockdown significantly increased wound closure. Centrifugal assay for cell adhesion 
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 v 
and hanging-drop assays, measuring hetero- and homotypic cell-cell interactions, showed 
significant decreases in adhesive strength with double knockdown only. Lastly, we showed the 
increased -catenin with -catenin loss appears to be regulated by the serine/threonine 
phosphorylation of -catenin by protein kinase A, introducing the possibility of a catenin sensing 
mechanism. In conclusion, -catenin loss is compensated by -catenin at AJs without negatively 
affecting other junctions; however, the function of -catenin as part of the Wnt pathway remains 
unfulfilled by -catenin. Thus, proposed anti-β-catenin therapies for HCC may be able to target 
aberrant -catenin in Wnt signaling specifically without negatively affect HCC prognosis, as 
long as -catenin is spared. 
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 1 
1.0  INTRODUCTION 
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide, and the severity of 
this disease has resulted in it becoming the third leading cause of cancer-related deaths 
worldwide [1, 2]. HCC commonly arises after chronic liver injury caused by diseases like 
hepatitis and non-alcoholic steatohepatitis (NASH), which most often lead to liver fibrosis and 
cirrhosis [3]. The increased incidence of Hepatitis C (HCV) in developing countries is a 
troubling statistic with respect to the incidence of HCC in the United States. Only about one-
third of all HCCs are curable by surgical resection, and the current treatments for the majority of 
HCC cases involve non-targeted palliative care, such as systemic chemotherapies [4]. Therefore, 
understanding and treating this disease at a cellular and molecular level is imperative in order to 
relieve this major health burden. 
Pathologically, an irregular distribution of -catenin has been described in up to 90% of 
HCC cases [5-7]. -Catenin is normally found at the hepatocyte membrane in adult livers, but in 
HCC there is often a decrease of membranous -catenin and/or an increase in nuclear or 
cytoplasmic -catenin localization [8]. Of the 90% of HCCs with abnormal -catenin staining, 
CTNNB1 gene mutations have also been reported in 30% of these cases [9]. Additional Wnt 
pathway mutations also contribute to abnormal -catenin stability/longevity and therefore 
aberrant distribution. HCC mutations and inactivations have been found in AXIN-1, AXIN-2, and 
Glycogen Synthase Kinase 3 (GSK3), all components of the Wnt signaling destruction 
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complex [10].  Based on the observation of -catenin mutations and mislocalizations in HCC, it 
has the potential to be a viable therapeutic target. Our lab and others have recently proposed a 
number of unique anti--catenin therapies for the treatment of HCC [11-13]. 
1.1 β-CATENIN 
-Catenin is a highly conserved protein with twelve core armadillo (arm) repeats flanked by N- 
and C-terminal domains which are unique to each armadillo family member. -Catenin has 
important roles in regulating embryogenesis, and also in maintaining normal cell homeostasis. -
Catenin classically influences the cell in two ways: 1) signal transduction via the Wnt/β-catenin 
pathway (1.1.1); and 2) cell-cell adhesion via the adherens junctions (1.1.2) (reviewed in [14]). 
The activity of -catenin in both signaling and cell-cell adhesion reveals the dynamic properties 
and general importance of this protein to overall cellular function. 
1.1.1 Wnt signaling 
In the canonical Wnt/-catenin pathway, the presence of the lipid-modified Wnt ligand initiates 
the formation of a ternary complex with the seven-transmembrane Frizzled receptor and Low-
density Lipoprotein Receptor Related Protein (LRP)5/6 which starts an intracellular signaling 
cascade. There are 19 human Wnt isoforms and 11 Frizzled isoforms known to date [15, 16], and 
the large number of possible combinations of ligand and receptor results in diverse possibilities 
for canonical and non-canonical Wnt signaling to influence the cell. In the presence of the 
ligand, Dishevelled dissociates from the receptor/ligand complex to initiate the cytoplasmic 
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signaling cascade where GSK3 is phosphorylated while in association with Axin and 
Adenomatous Polyposis Coli (APC) in a multi-protein destruction complex. The phosphorylation 
of GSK3 leads to its inactivation as a kinase and thus results in hypophosphorylation of -
catenin, releasing the stabilized -catenin from Axin/APC so that it can translocate to the nucleus 
to activate target genes (Figure 1A). -Catenin cannot bind DNA directly, but acts as a co-
activator by associating with T-cell Factor/Lymphoid Enhancer Factor (TCF/LEF) transcription 
factors. TCF/LEF binds to DNA via their High Mobility Group (HMG) domain and 
transactivates -catenin/TCF/LEF target genes, including Glutamine Synthetase (GS) and 
CyclinD1 which influence cell proliferation and differentiation. In the absence of ligand, at 
steady state, or in the presence of Wnt signaling antagonists such as Dickkopf (Dkk), -catenin is 
phosphorylated at Ser45 by Casein Kinase Iα (CK1) via a similar intracellular cascade involving 
Dishevelled and the Axin/APC complex [17]. This phosphorylation event leads to the 
phosphorylation of -catenin by GSK3 on Ser33, Ser37 and Thr41 to destabilize -catenin and 
target it for degradation via the ubiquitin ligase -Transducin Repeat-Containing Protein 
(TrCP) and the proteasome (Figure 1B) [18]. 
In addition to the canonical Wnt/-catenin signaling pathway, Wnt ligands are able to 
participate in non-canonical, -catenin-independent signaling pathways. The two most well 
understood non-canonical pathways are the Planar Cell Polarity (PCP) and Wnt/Ca
2+
 signaling 
pathways, both involved in dorsal-ventral axis specification [19]. The PCP pathway regulates 
actin polymerization via small GTPases in a transcriptional-independent manner which 
influences cell polarity and migration [19]. Additionally, Wnt/Ca
2+
 pathway involves the Wnt-
dependent regulation of intracellular Ca
2+
 levels via Phospholipase C, which in turn modulates 
 4 
Ca
2+
-dependent effectors: Calcineurin, Calcium/Calmodulin-dependent kinase II (CaMKII), and 
Protein Kinase C (PKC) [19]. 
Furthermore, there are also Wnt-independent, and therefore also non-canonical avenues 
by which -catenin influences target gene expression. Both PKA and Akt have been shown to 
directly phosphorylate -catenin without affecting canonical Wnt/-catenin signaling. PKA 
phosphorylates -catenin at Ser552 and Ser675, which facilitates TCF-dependent -catenin 
transcription involving the coactivator Cyclic AMP Response Element-Binding Protein (CBP) 
[20]. This PKA/-catenin signaling is independent of GSK3-dependent -catenin 
phosphorylation/stabilization, and does not use the destruction complex machinery to help 
induce target gene transcription [20]. Akt also phosphorylates -catenin at Ser552 which 
redistributes -catenin to the cytoplasm/nucleus and increases TCF/LEF-1 transcription in a 
GSK3-independent manner [21]. Additionally a Wnt-independent regulation of -catenin 
signaling via its interaction with Hepatocyte Growth Factor (HGF) receptor/tyrosine kinase c-
Met has also been elucidated in hepatocytes [22]. Stimulation of hepatocytes by HGF was also 
shown to increase Ser654 and Ser670 phosphorylation of -catenin causing its dissociation from 
c-Met and translocation to the nucleus [23]. The canonical and non-canonical pathways are not 
mutually exclusive within the cells, but work with one another to coordinate the efforts of the 
cell [20, 21]. 
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Figure 1. Canonical Wnt/-Catenin signaling pathway. (A) With and (B) without Wnt ligand. Dkk is a 
Wnt-specific inhibitor; * indicates phosphorylation. 
1.1.2 Adherens junction (AJ) 
At a steady state and without Wnt ligands,-catenin can most often be found at the cell 
membrane in the adherens junction (AJ) complex. In AJs, -catenin links the classical/type-I 
transmembrane cadherins (E-, P- N-cadherins and N-cadherin 2) to -catenin and the actin 
cytoskeleton via -catenin arm domain interactions (Figure 4A; see also section 1.4.2). A 
cadherin/catenin complex with E-/N-cadherin and either -catenin, p120-catenin or-catenin 
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(plakoglobin)  is assembled in the endoplasmic reticulum of the cells and is required for the 
membrane localization of cadherins [24, 25]. Importantly, the binding of these catenins help 
stabilize E/N-cadherin by masking the cadherin is proline (P), glutamate (E), serine (S), and 
threonine (T) (“PEST”) domain, which has an ubiquitin/proteasome recognition motif [26]. 
Therefore, this cadherin/catenin complex initiation is important to overall stability of not only the 
cadherins but also the AJs. 
Currently, it is still unclear whether this membrane-bound pool of -catenin also has 
signaling capabilities. It has been historically thought that -catenin is able to balance its 
adhering and signaling roles through tyrosine kinase and phosphatase activities in order to 
mediate both AJ and Wnt signaling tasks [14, 27]. Studies have shown that tyrosine 
phosphorylation of -catenin at Tyr142, Tyr654 and also Tyr489, which are near the cadherin-
catenin interacting surface, confer AJ integrity. Phosphorylation of Tyr654 via Src kinase or 
Epidermal Growth Factor (EGF) receptor leads to -catenin‟s uncoupling from the E-cadherin. 
This also occurs when -catenin is phosphorylated at Tyr489 via Abl [27]. Additionally, the 
phosphorylation of Tyr142 via Fyn, Fer kinases, along with c-Met leads to the uncoupling of the 
-catenin/-catenin complex, which also lead to the dissociation of the AJ resulting in increased 
cytoplasmic -catenin [14, 28]. But whether an increase in cytoplasmic/nuclear -catenin 
correlates with increase -catenin signaling is still under debate [29]. 
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1.2 β-CATENIN IN LIVER HOMEOSTASIS 
-Catenin is a critical protein in liver development, hepatic zonation, metabolism, regeneration, 
and overall liver health [10]. -Catenin has a very precise spatiotemporal expression in the 
developing embryo, and is especially important for specification of hepatic fate, hepatocyte 
differentiation, and expansion of the liver bud. An embryonic stem cell deletion of -catenin 
results in lethality at 7 days post-coitum as a result of ectodermal defects indicating the 
importance of -catenin in development and gastrulation [30]. The expression of -catenin peaks 
in the developing liver at mouse embryonic day 10 (E10) through E12 in the bi-potent 
hepatoblasts where staining is localized in both the nucleus and cytoplasm [31]. At these times, 
proliferation of the developing liver also peaks, suggesting -catenin expression is key for 
hepatic morphogenesis [31]. After the-catenin peak at E12, there is a sharp decrease in total 
full-length hepatocyte -catenin. Interestingly, a truncated form of -catenin appears at day 
E12.5 and persists in the absence of full-length -catenin until just before birth [31, 32]. Recent 
work by our lab has shown that the truncated -catenin species appears preferentially in 
embryonic hepatocytes and increases expression of differentiation-specific genes [32]. In 
addition to its role in embryonic hepatocyte fate, -catenin is essential for the specification of 
hepatoblasts into biliary epithelial cells, as a loss in embryonic -catenin leads to primitive bile 
duct paucity [33].  
Postnatally, -catenin is also important in neonatal liver growth. -catenin is responsible 
for hepatocyte proliferation in mice, especially from day 0 to 30 after birth [34, 35]. It has also 
been shown that the distribution of -catenin and destruction complex protein APC help drive 
lover zonation. The liver is organized into functional units called lobules, where portal triads 
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(hepatic portal vein, hepatic artery, and bile duct) surround a central vein in a hexagonal pattern. 
This organization helps with specific metabolic events, as blood flows through the lobules 
towards the central vein and bile moves in the opposite direction towards the portal triad into the 
bile ducts (Figure 3A). -Catenin activation and expression of its target genes, such as 
Glutamine Synthetase, is observed in the pericentral liver lobule (near the central vein) whereas 
APC, a -catenin degrading protein, is expressed in the periportal area of the liver (near the 
portal triad) [36]. Furthermore, -catenin is able to control xenobiotic metabolism, through its 
regulation of cytochrome P450s in the liver, such as CYP2E1 and CYP1A2, which also follow a 
pericentral patterning [34]. As a result, -catenin-driven glutamine, ammonia, and xenobiotic 
metabolism are major functions of -catenin in an adult liver [34, 37, 38]. 
The adult liver also has a unique capacity to regenerate itself in a highly regulated 
manner. In mouse and rat models, a 2/3 partial heaptectomy is used to gauge the regenerative 
response of the liver (see 7.2.1 for surgery details). As -catenin is so critical for liver growth, it 
is reasonable to assume that it also has an important role in liver regeneration as well. After 
surgical resection of the liver in rats, overall -catenin levels are increased with fifteen minutes 
with preferential nuclear localization, and the influence of nuclear -catenin is sustained for up 
to 48 hours [39]. Studies have shown that this -catenin increase is not due to transcriptional 
changes of the -catenin gene Ctnnb1, but is due to a decrease in protein degradation as a result 
of decreased serine phosphorylation [39]. -Catenin appears to have a direct influence on 
proliferation in the regenerating liver, as an increase in -catenin target genes such as CyclinD1 
are noted at similar times of -catenin nuclear localization [39]. 
Additionally, to further assess the impact of -catenin in the liver, our lab and others have 
recently created a hepatocyte-specific (post-natal) -catenin knockout mouse (KO) using Cre-
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Lox recombination system in which -catenin is preferentially deleted from albumin-secreting 
hepatocytes of the liver (see 7.1.1 for breeding scheme) [34, 37, 40]. The key observations found 
by our lab were that the KO mice had a decreased liver-weight-to-body-weight-ratio (about 
25% smaller), a decrease in basal proliferation, and an increase in apoptosis [34]. These mice 
showed marginal intrahepatic cholestasis and mildly anomalous biliary canalicular architecture, 
but surprisingly there was no apparent defects in cell polarity or adhesion [34, 41]. Novel gene 
targets of -catenin were also discovered, such as vitamin C biosynthetic protein Regucalcin 
[34]. In the context of regeneration, -catenin-null livers were able to fully recover after surgical 
resection, though the regenerative process was delayed; specifically, peak proliferation was 
delayed by at least 24 hours in the KO mice [34]. Therefore, our characterization of this model 
showed that -catenin is essential for overall liver health, but loss of -catenin in hepatocytes 
does not lead to liver failure.  
1.3 β-CATENIN IN LIVER PATHOLOGIES 
Dysregulation of -catenin plays a significant role in mediating common hepatic pathologies, 
including hepatocellular carcinoma (HCC), focal nodular hyperplasia, hepatic adenoma, 
hepatoblastomas, hepatic fibrosis, and cholangiocarcinomas [10]. However, characterization of 
KO mice has shown that alterations in -catenin alone do not necessarily lead to any one liver-
specific disease [34, 42, 43]. In most pathological cases exon deletions or stabilizing point 
mutations of -catenin lead to an increase in -catenin signaling. In the case of cancer, the 
increase in -catenin can increase survival and proliferative genes, giving the cancer cells a 
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growth advantage. Therefore, the possibility of targeting -catenin therapeutically has been 
highly considered in clinical settings in recent years, especially for HCC [44-46]. 
1.3.1 Targeting β-catenin in HCC 
Targeting -catenin for HCC is inevitable [11, 12, 44-47]. Therefore, our lab, among others, has 
started exploring the efficacy of these clinically relevant anti--catenin therapies for HCC in 
vitro and in vivo. Our lab began by exploring drugs which were been pre-approved for HCC or 
other pathologies to see if there were any compounds that already existed in which the 
mechanism of action involved -catenin. In this way, we could start to test the viability of anti--
catenin treatments for HCC.  
A number of studies have shown an increase in the enzyme cyclooxygenase (COX)-2 in 
HCC patient tissue samples [48-51]. COX-2 is an enzyme that is important in synthesis of 
prostaglandins, which mediate pain and inflammation. Additionally, COX-2 inhibitors are 
common non-steroidal anti-inflammatory drugs (NSAID) routinely used to control pain and 
inflammation. Previously, other groups have looked into treating HCC with the COX-2 inhibitor 
Celecoxib [52]; however, some serious side effects have been associated with Celecoxib (renal 
failure, heart attack, stroke, thrombosis). Therefore, our lab investigated the role of the NSAID 
R-Etodolac (1,8-diethyl-1,3,4,9-tetrahydropyrano-[3,4-b] indole-1-acetic acid) to compare its 
efficiency to Celecoxib. R-Etodolac is an NSAID which lacks COX-inhibitory activity, and 
therefore reduces the serious side effects associated with COX-inhibition [53]. Our data showed 
that the mechanism of action of both Celecoxib and R-Etodolac included a reduction of total and 
mutant -catenin levels in Hep3B and HepG2 HCC cells, in addition to a decrease in Wnt-
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dependent signaling and downstream -catenin targets [11]. R-Etodolac was more effective at 
lower doses (400 M), and also decreased transcription of C. Interestingly, targeting -
catenin in HCC cells with R-Etodolac also enhanced the interaction of -catenin with E-cadherin 
[11]. This study showed that it was the NSAID effects of the R-Etodolac which decreased -
catenin levels. Thus, the effectiveness of the clinically-relevant NSAID R-Etodolac in reducing 
-catenin levels presents an attractive anti--catenin therapy for HCC.   
For another potential anti--catenin drug, we looked at a drug already used for liver 
diseases. In the clinic the antiviral Pegylated-Interferon-2a (peg-IFN) is one of the most 
common drugs used to treat HCV. HCV infection is one of the largest risk factors for HCC since 
it causes chronic liver injury. Additionally, HCV-associated HCCs have been characterized as 
having a high percentage of -catenin mutations and also high levels of cytoplasmic and nuclear 
-catenin as a result of Wnt pathway activation [54, 55]. Interestingly, when patients were 
treated for HCV with interferons (IFNs), the onset of HCC was delayed, or even prevented, even 
if the HCV was not effectively treated [56-58]. Our lab investigated the molecular mechanism of 
peg-IFN on -catenin and also HCC. The results showed that peg-IFN was able to decrease Wnt 
signaling activity in human HCC cell lines with and without -catenin mutations [12]. Our 
studies showed that peg-IFN up-regulated Ran Binding Protein-3, a -catenin nuclear export 
factor, which led to the decrease in nuclear -catenin and therefore Wnt signaling [12]. In 
addition to in vitro studies, transgenic mice with an activating -catenin mutation affecting Ser45 
were treated with the hepatocarcinogen N-diethylnitrosamine (DEN) and showed a decrease in 
tumorigenesis with peg-IFN treatment via decrease in hepatocyte proliferation [12]. As with R-
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Etodolac, IFNs are also a set of attractive anti--catenin drugs which have already been tested for 
safety in patients. 
Novel treatments for cancers with aberrant -catenin expression are still being developed. 
The new form of molecular treatments comes as small molecule inhibitors which target specific 
molecular interactions within transformed cells. The drug ICG-001 was recently identified to 
selectively disrupt the interaction of -catenin and its transcriptional coactivator CBP in colon 
cancer cells [13]. This drug was effective in reducing proliferation and inducing selective 
apoptosis of cancer cells via reduced TCF-dependent Wnt signaling [13]. This inhibitor was 
effective without unintentionally interfering with other -catenin protein-protein interactions, 
like -catenin/p300 [13]. Interestingly, ICG-001 was able to exert its effect without changing the 
protein expression level of -catenin [13]. Thus, this molecule exemplifies the ability of novel 
small molecules to be used to target aberrant -catenin activity in a highly selective and 
personalized manner. Currently, our lab is focusing on expanding on these types of -catenin 
inhibitors, in order to find a better match for HCC-specific therapies. 
The caveat for treating HCC with anti--catenin therapies, however, is that -catenin has 
dual roles in the cell as a component of the Wnt signaling pathway and also the AJs (see 1.1). 
Therefore, the question remains whether targeting -catenin therapeutically will have negative 
unintended secondary effects as a result of targeting -catenin at the cell-cell adhesions (Figure 
2). As mentioned previously, it is uncertain whether the pool of -catenin found in Wnt singling 
is the same as that found at the AJs [14]; therefore, we cannot be certain of the outcome of 
clinically targeting -catenin until we specifically address this issue, or determine whether there 
is a compensatory mechanism in place to keep the cell-cell junctions intact. However, promising 
data from our lab indicates that decreasing -catenin in vitro leads to decreased -catenin nuclear 
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localization and signaling, decreased cell survival, proliferation, and soft-agar colonization of 
human HCC cells, without overtly affecting the cell adhesions [59]. Additionally, the conditional 
knockdown of -catenin in hepatocytes did not lead to dissolution of the liver [34], all of which 
suggests that there is a presumptive compensation for -catenin loss does not have oncogenic 
effects of increasing survival and proliferation of HCC cells. 
 
 14 
 
Figure 2. Schematic of targeting -catenin for hepatocellular carcinoma. (A) The literature has shown that -
catenin activation via Wnt pathway or -catenin alterations leads to increased Wnt signaling and affects the 
progression of HCC. (B) Proposed anti--catenin inhibitors for the treatment of HCC hypothesize a decrease of 
HCC. (C) However, -catenin‟s dual role in at the hepatocyte adherens junctions may complicate the proposed anti-
-catenin therapies; if targeting -catenin for HCC is detrimental to the adherens junctions, the -catenin inhibitors 
may increase metastasis or invasion of the cancer cells and/or worsen the prognosis of HCC or other cancers. 
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1.4 HEPATOCYTE JUNCTIONS 
Junctions are critical to overall structure and proper function of the liver. Although cell-cell 
junctions are rare in non-parenchymal cells of the liver, they are essential for hepatocytes 
polarity and organization. Hepatocytes are the primary parenchymal cells of the liver and play a 
role in integrating exocrine and endocrine functions of the liver through discrete membrane 
domains. Cell-cell junctions not only supply points of adhesion for hepatocytes, but also 
contribute to intercellular and intracellular communication. For this reason, junctions are 
frequently affected by in liver injury, toxicity, infection, and cancer [60-63]. The hepatocyte 
junctions can be divided into three groups: anchoring (AJ, desmosome), occluding (tight 
junctions), and communicating junctions (gap junction) (reviewed in [64]) (Figure 3). 
 
 
 
Figure 3. Hepatocyte junctions. (A) Illustration of the segregation of liver cell types and liver-specific functions, 
which are influenced by cell-cell junctions (image adapted from [65]) (B) Schematic of common cell-cell junctions 
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of the polarized hepatocytes (BC = bile canaliculus; AJ= adherens junction; Desmo. = desmosome; TJ = tight 
junction; GJ = gap junction; IF = intermediate filament). 
1.4.1 The blood-bile barrier 
The liver relies on proper organization through organized cell-cell adhesions to facilitate the 
critical and complex physiological functions of the liver. The apical surface of the hepatocyte 
generates bile while the basal surface helps exchange metabolites, other nutrients and toxins with 
the sinusoidal blood. Within the liver, bile flow is directed from the centrizonal to the periportal 
zone of the liver lobule. Newly synthesized bile is collected in the bile canaliculi, which connects 
to the bile duct at the portal triad. Bile is then transported to extrahepatic biliary tree and 
eventually secreted into the intestines. Thus blood and bile are properly segregated in the liver by 
junctional seals. A breach in the junction can disrupt the blood-bile barriers and cause changes in 
bile flow and ultimately cholestasis [66]. TJs are the main occluding junction of the liver creating 
seal which regulates the flow of molecules between hepatocytes in the paracellular space, keeps 
bile and blood from mixing, and maintains cellular polarity [67, 68]. However, with documented 
junctional cross-talk between AJs and TJs [69], AJs and desmosomes [70], along with AJs and 
gap junctions [71] and TJs and gap junctions [68] (see 1.5), it is unlikely that the TJs are the only 
junctions responsible for functional segregation. 
1.4.2 Anchoring junctions (adherens junctions & desmosomes) 
The anchoring junctions help attach cells together via Ca
2+
-dependent dimerization of 
extracellular cadherins and internal linkage to the cytoskeleton. As mentioned above in 1.1.2, the 
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adherens junctions (AJs) are composed of classical cadherins and catenin armadillo family 
members that attach cells to one another via extracellular cadherin homodimers and link the 
plasma membrane to the actin cytoskeleton (Figure 4A). From extracellular to the cytoskeleton, 
the AJs in the hepatocytes normally consist of E- or N-cadherin bound to -catenin and linked to 
-catenin and then F-actin microfilaments. Auxiliary catenins, such as p120-catenin, are attached 
to the cytoplasmic domain of E-cadherin, but do not participate in the physical linking of the 
plasma membrane to the cytoskeleton; however, these catenins participate in junctional 
maintenance by facilitating cadherin turnover and mediating kinase recruitment [14, 27, 72]. In 
epithelial cells, including hepatocytes, the AJs are located near the apical surface of the cell, just 
below the tight junctions on an apical-basal axis (Figure 3B). The AJs form a belt-like band 
which is enriched for F-actin, which not only physically anchors cells together but may also 
bridge the cytoskeletal networks from one cell to another [73]. In addition to adhesion and 
polarity, AJs and their components are known to help with xenobiotic biotransformation [74] and 
albumin secretion [75] in the liver. 
Desmosomes resemble AJs, but appear later in the evolutionary tree; however, these 
junctions are not redundant, and both are required for vertebrate existence as indicated by the 
lethality of global knockouts of their core catenin proteins [30, 76]. In the liver, desmosomes are 
found mainly along the lateral surface of hepatocytes [77]. Similar to the AJs, desmosomes are 
composed of cadherins (desmocollins (Dsc) 1-3 and desmogleins (Dsg) 1-4) which also link the 
cells together in the extracellular space; however, desmosomal cadherins can also interact as 
heterodimers. The desmosomes connect the plasma membrane proteins to the actin cytoskeleton 
through cadherin interactions with catenin proteins -catenin (plakoglobin) and plakophilin (Pkp; 
Pkp1-4), and catenin interactions with the adaptor protein desmoplakin (DP; DP1-2) which is 
 18 
subsequently linked to the cytokeratin intermediate filaments (Figure 4B). The desmosomes 
appear as electron-dense structures via electron microscopy, with distinct outer dense plaques 
consisting of Dsg, Dsc, -catenin, Pkp and DP, and an inner dense plaque where the intermediate 
filaments loop back on each other. Though the desmosomes are made up of similar components 
as the AJs, their function is quite unique. Desmosomes are found below the AJs on an apical-
basal axis, but are scattered through the lateral membranous space, resembling “spot welds” 
(Figure 3B). The main function of the desmosome is to dissipate mechanical stress, and is 
therefore critical in highly stressed organs such as the heart and skin [76]. To confer a higher 
than normal stress tolerance, the desmosomes are involved in specialized hyper-adhesion, where 
the mature desmosomes are locked into a highly-ordered plaques characterized by their 
resistance to disruption by calcium-chelators [78]. Though desmosomes are recognizable in liver 
tissue [77], the role of desmosomes for overall liver function has not been critically addressed in 
the literature to date. 
 
 
 
Figure 4. Anchoring and occluding junctions of the liver. (A) Adherens junction; (B) desmosome; and, (C) tight 
junction. The tight junction adaptor/scaffold proteins of the hepatocytes are ZO-1/3, MAGI1/3, PAR-3/6, MUPP1 
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and cingulin; the transcriptional regulators are ZONAB and symplekin; and the regulatory proteins are aPKC, and 
small GTPases [64]. 
1.4.3 Occluding junctions (tight junctions) 
Occluding junctions encircle the cell at the apical membrane and segregate hepatocyte cellular 
domains [79]. Tight junctions (TJs) are considered the main occluding junctions of the liver 
where they surround the bile canaliculi and segregate the flow of bile, which can be caustic to 
hepatocytes (Figure 3B). TJs are composed of a wide variety of proteins which can be classified 
into two groups: transmembrane components (i.e. occludin, claudins, Junctional Adhesion 
Molecules (JAMs), and Coxsackieadenovirus Receptor (CAR)) and cytosolic components (i.e. 
Zonula Occludens proteins (ZO), cingulin, 7H6 antigen, etc.) (Figure 4C) [64]. Within the 
cytosolic TJ components, there are also three sub-groups, which are further classified based on 
their functional properties: adaptor/scaffolding proteins (core junctional proteins), regulatory 
proteins (such as small GTPases), or transcriptional regulators [64]. With so many sub-groups 
and possible combinations of TJ components, the number of TJ proteins discovered at the 
hepatocyte junction is constantly growing. The core proteins of the TJs are the transmembrane 
JAMs, claudins and occludin. There are four JAMs and even more related Ig-superfamily 
members, but only one isoform of occludin. Claudins make up a large family of proteins, and 
there are currently 20 known claudin family members that have specialized expression and 
function within each tissue type. The claudins expressed in different liver cell types are: 
claudins-1, -2, and -3 in the bile canaliculus and hepatocytes; claudin-5 in endothelial cells of the 
liver; and claudins-7, -8, and -14 liver cell-specific expression has not be specified [64, 68]. 
Interestingly, some TJ proteins also exhibit lobular expression in the liver. Claudin-3 is 
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uniformly expressed in the liver, whereas claudin-2 is increased in the pericentral areas of the 
liver [80], which indicates that they play a role in liver zonation and/or metabolism. 
1.4.4 Communicating junctions (gap junctions) 
Communicating gap junctions of the liver are composed of connexon proteins organized into 
channels by the interaction hemichannels of adjacent cells. Each hemichannel is composed of a 
combination of six connexons (Cx). Currently, there are over 20 connexons described in the 
literature, each having specialized expression in different cell and tissue types [64].  In the liver 
the connexons which have been described between hepatocytes are: Cx26, Cx31.9/30.2, Cx32 
(the most abundant Cx in the liver at around 90%), Cx37, and Cx39, and Cx 43 [64, 81]. Gap 
junctional intercellular communication (GJIC) allows molecules to move from one hepatocyte to 
another through these channels via passive diffusion of small or hydrophilic molecules (Figure 
3B). In the liver, gap junctions are known to help with xenobiotic biotransformation [74], bile 
secretion [82, 83], albumin secretion [84], and glycogenolysis [85], both on their own and in 
concert with hepatocyte AJs. 
1.5 JUNCTIONAL CROSS-TALK 
As mentioned above in 1.4.1, there are many known nodes of cross-talk between AJs, 
desmosomes, TJs, and gap junctions. These are important redundancies built into the physiology 
of epithelial cells which undoubtedly help in the maintenance of cell-cell adhesions in the event 
of junctional insults, such as viral infection [60], barrier disruption [66], and therapeutic 
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treatments. With the inevitability of targeting Wnt/-catenin and AJ protein -catenin for HCC 
(see section 1.3.2), it is important to understand the potential nodes of cross-talk which may be 
altered with these treatments. 
The cross-talk of anchoring AJs and communicating gap junctions has been historically 
explored in the heart where gap junctions are most abundant. The formation of gap junctions 
plaques are known to follow the formation of stable cell-cell contacts, since GJIC requires the 
junctions to endure large amounts of sheer stress [86]. As a result, disruption of AJ cadherins are 
known to negatively affect gap junctions [87, 88]. Moreover, other research has shown more 
direct links between AJ and gap junctions. Experiments in cardiomyocytes show that Cx43 
appears to co-localize with -catenin at AJs in response to Wnt signaling [89]. These interactions 
not only highlight the cross-talk between AJs and gap junctions, but also -catenin‟s potential 
regulatory roles of other junctions via Wnt signaling. Additionally the interplay of AJs and gap 
junctions in the liver appear to be important for the induction of cancer. In liver hepatomas, Cx26 
levels have been shown to cause induction of AJ protein E-cadherin in order to suppress 
metastatic phenotypes [90]. 
Recently in the literature, the notion of cross-talk between the AJs and the occluding TJs 
has been explored in the liver [41, 69, 91]. Though AJ and TJs are expressed proximally in the 
hepatocytes, they have completely separate anchoring and occluding roles respectively; 
therefore, it is interesting to postulate a cross-talk node between these two junctions. It has been 
shown that a decrease in JAM-A levels leads to an increase in AJ E-cadherin in HCC cell lines 
[69]. Konopka et al. hypothesize that his change in AJ protein with JAM-A disruption may be an 
attempt of the liver cells to re-establish polarity and adhesiveness [69], but more work needs to 
be done to investigate whether the changes in the AJ actually help functionally relieve the TJ 
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disruption caused by a loss of JAM-A. Additionally, the cross-talk between AJs and TJs is also 
mediated via -catenin-dependent signal transduction regulation of gene expression. Research 
has shown that claudin-2 is a downstream target of the Wnt/-catenin pathway, indicating a 
direct influence of this signaling pathway on TJ protein expression [8, 92]. Conversely, JAM-A 
has been shown to influence intestinal cell proliferation by inhibiting Akt/-catenin signaling 
[93]. These results highlight the interconnectedness of all epithelial junctions, despite their 
unique functionalities. 
Lastly, though the AJs and desmosomes are known to share a common protein 
constituent under certain physiological conditions (-catenin), there is surprisingly little research 
on cross-talk between these two anchoring junctions, especially in the liver. As with gap 
junctions, the assembly of AJs must precede desmosome formation [94-105]. The inhibition of 
the AJ protein E-cadherin not only decreases AJ formation, but also dampens desmosome 
formation [100, 106]. Additionally, without -catenin AJs can form, but desmosomes cannot [70, 
107]. Not surprisingly, two groups have implicated -catenin as the cross-talk agent between AJs 
and desmosomes since it can be localized to both junctions. Both groups have shown that it is the 
interaction of -catenin and AJ E-cadherin which is necessary for the assembly of desmosomes 
[70, 108].  More recently, it has been shown that the presence of desmosomal plaque protein 
plakophilin-3 is also essential in this complex to initiate desmosome formation in epithelial cells 
[108]. It is thought that even though -catenin is an unessential AJ protein, the -catenin/E-
cadherin/plakophilin-3 complex is still needed to recruit desmosomal proteins to the cell 
membrane [108], blurring the lines of AJ and desmosomal assembly. Together this data suggests 
that -catenin may play a rather dynamic role in regulating multiple junctions. 
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1.6 β- VERSUS γ-CATENIN 
For many years -catenin and -catenin were indistinguishable by investigators of biological 
systems, especially since the protein “armadillo” sufficed for both proteins in Drosophila. 
However, - and -catenin are unique entities that developed distinct functions as far back as 
vertebrate divergence [109, 110]. At times -catenin plays a redundant role to -catenin in the 
AJ, but is uniquely qualified as a major component in the desmosomes [76, 107], highlighting 
the non-identical roles of these two proteins (see also 1.4.2). Though -catenin can intervene at 
the AJ when -catenin is lost, the reciprocal compensation of -catenin for -catenin loss at the 
desmosome is not functional [107]. The differences of - and -catenin in cell-cell adhesions and 
Wnt signaling will be expanded upon in the upcoming sections on -catenin (1.7). 
1.7 γ-CATENIN 
γ-Catenin (also known as plakoglobin) is highly homologous to -catenin with ~80% sequence 
similarity in the arm domains, and 45-57% and 15-27% N- and C-terminal domain identities 
respectively [111, 112]. -Catenin is essential in embryonic development as well, as a global 
knockout of this protein is embryonic lethal in mice between day E12 and E16 as a result of heart 
and skin defects [76], compared to day E7 lethality with an embryonic -catenin knockout[30]. 
The primary functional role of -catenin is in cell-cell adhesion, where it helps link cadherins to 
the cytoskeleton in the desmosomes (1.4.2; Figure 4A-B). 
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1.7.1 Cell-cell adhesion 
It is well accepted that -catenin is an essential catenin of the desmosome (see 1.4.2; Figure 4B). 
As discussed above, recent evidence has also revealed the role of -catenin as an important 
protein in both desmosome and AJ assembly [70, 108]. Additionally, -catenin has the capacity 
to bind E-cadherin at the AJ, especially with a loss or decrease of -catenin [113-119]. Structural 
studies indicate that - and -catenin have identical interactions with E-cadherin [111]; however, 
it is unclear whether this -catenin/E-cadherin junction is functionally equitant to the -
catenin/E-cadherin AJ.  
As with -catenin, -catenin is able to balance its structural and functional roles through 
tyrosine kinase and phosphatase activities [114], where it is trafficked between the AJs, 
desmosomes, and other intercellular locations. Tyrosine phosphorylation of -catenin at Tyr549, 
Tyr693, Tyr724 and Tyr729 by Fer and Fyn kinases or EGFR decreases -catenin‟s binding to 
DP and increases its binding with -catenin; conversely, phosphorylation of Tyr643 by Src 
kinase has the opposite effect and decreases -catenin‟s binding to E-cadherin [114]. Though the 
residues responsible for -catenin‟s localization to the AJs and desmosomes are well established, 
the mechanism responsible for -catenin‟s stabilization at specific parts of the membrane or in 
the cytoplasm/nucleus are less clear. -Catenin has key serine residues, such as Ser37, whose 
phosphorylation via GSK3 and other kinases dictate its stabilization and translocation to the 
nucleus (see 1.1.1). However, the corresponding mutations on -catenin (Ser28Ala) do not infer 
stability [112]. Nonetheless, studies have shown that serine and/or threonine phosphorylation is 
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able to stabilize -catenin [115]; but, the specific residues, responsible kinases, and physiological 
cues for serine and/or threonine phosphorylation/stabilization of -catenin are still unknown. 
1.7.2 Wnt signaling 
The role of γ-catenin in Wnt signaling is still controversial. It has been shown that -catenin can 
interact with many Wnt signaling components, including: Axin/APC [112, 120, 121], GSK3 
[120], TCF/LEF [122, 123], and βTrCP [124]. Additionally, as with -catenin, -catenin is up-
regulated in response to Wnt-1 ligand [125]. However, the question remains whether these 
associations are functional. The evidence is stacked against a signaling role of -catenin in the 
Wnt pathway, except in cases where there is a complete loss of -catenin [126, 127]. However, 
the competition between - and -catenin for similar cytoplasmic and nuclear binding partners 
makes it difficult to differentiate their roles within the cell, and also complicates the research of 
both - and -catenins individually and together.  
The reason for -catenin‟s preferential participation in Wnt signaling might be driven by 
-catenin‟s solubility and localization within the cell. -Catenin has a greater propensity to 
localize to the cell membrane compartment than -catenin, as 85% of a cell‟s -catenin is Triton 
X-100 insoluble (actin cytoskeleton-sequestered), and only 50% of the cell‟s -catenin is 
insoluble [124]. Therefore, -catenin‟s tendency to remain in the membrane may help -catenin 
better localize to the cytoplasm and occupy the cytoplasmic Wnt signaling machinery [122, 124]. 
Overexpression of -catenin also has been shown to displace -catenin from the AJs, leading to 
an increase in cytoplasmic, and even nuclear -catenin, which may influence the signaling 
capacity of -catenin [122, 128, 129]. Another theory of how -catenin can guide Wnt/-catenin 
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signaling is that increased -catenin in the cytoplasm could overload or preferentially occupy the 
destruction complex components (Axin or APC) or the βTrCP degradation machinery, 
decreasing the amount of -catenin degradation, and consequently increasing in the signaling 
pool of -catenin [112, 129, 130]. Therefore, when -catenin is increased/over-expressed, it may 
actually be -catenin signaling in the nucleus, and not -catenin. Neither - nor -catenin is able 
to bind to DNA directly, but both have been shown to utilize HMG box-containing DNA binding 
proteins to drive transcription [123]. However, -catenin co-precipitates with LEF1 and TCF4 
with higher affinity than -catenin in vitro [112, 122, 131]. Therefore, the competition for Wnt 
signaling may be influenced by the intrinsic affinities of - and -catenin for their shared binding 
partners. The current tools used to measure Wnt-dependent signaling are unable to differentiate 
between - and -catenin binding [122, 127]. 
Moreover, some groups hypothesize that -catenin might actively oppose Wnt signaling 
in the cell. More than one group has reported that in their model system γ-catenin binds to TCF4 
but then sequesters it in the cytoplasm, rendering it useless for - or -catenin driven 
transcription [123, 130-133]. The Alzheimer disease protein presenilin-1 has been shown to 
mediate this sequestration of -catenin/TCF4 to the extranuclear compartment [133]. Detailed 
mapping of the TCF4 binding regions of - and -catenin show that these proteins have 
independent interaction sites on TCF4, but that binding of -catenin to TCF4 hinders its ability to 
bind DNA [131]. Additionally, Zhurinsky et al. showed that -catenin could form an association 
with LEF1, but that a -catenin/LEF1/DNA complex never existed. This group hypothesized that 
is was the C-terminal of -catenin which inhibited the -catenin/LEF complex from binding 
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DNA [123]. This may explain why the C-terminal regions of - and -catenin are the most 
dissimilar. 
Despite all the arguments against -catenin in Wnt signaling presented above, this protein 
still appears to have intrinsic signaling capabilities. Independent of -catenin, many reports have 
shown that -catenin has its own set of transcriptional targets, including PTTG1, NME1, and c-
Myc [121, 134-136]. In addition to Wnt signaling, -catenin has been connected with Akt, Erk, 
and Rho GTPase signaling pathways [135, 137]. Interestingly, unlike -catenin, it is well 
accepted that the -catenin found at the membrane is the same pool/species involved in signaling 
[138]. Based on emerging data with respect to Wnt-independent -catenin signaling, more 
attention needs to be given to -catenin as an independent signaling effector in the cells. 
Additionally, more rigorous research efforts should be made to distinguish -catenin from the 
Wnt signaling pathway, instead of assuming it always exerts its influence in the same way as its 
non-identical sibling -catenin. 
1.8 γ-CATENIN IN HUMAN DISEASES 
Alterations in the structure of -catenin play a significant role in several human pathologies, most 
commonly in those tissues which rely on the adhesive strength of the desmosomes. Thus, 
changes in the membrane localization -catenin have been implicated in skin/heart pathologies, 
but also in cancer. Unlike -catenin, there are very few cases of point mutations causing aberrant 
-catenin expression; regardless, changes in -catenin localization have been noted in the 
development, progression and metastasis of many types of cancer (see 1.8.2).  
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1.8.1 Skin and heart diseases 
Classical diseases of the desmosomes, and desmosomal protein components, most often present 
as skin and heart defects. Therefore, -catenin mutations most often lead to the inherited diseases 
arrhythmogenic right ventricular cardiomyopathy (ARVC) and/or diffuse non-epidermolytic 
palmoplantar keratoderma with woolly hair and cardiomyopathy (“Naxos” or “Woolly hair” 
syndrome). These are the only two diseases known to have mutated forms of -catenin. The 
ARVC -catenin mutation has been identified as Ser39_Lys40insSer, where an extra serine 
residue is inserted in the N-terminus resulting in preferential ubiquitination and degradation of 
the mutant -catenin protein [139]. In Naxos syndrome, the 2157del2 mutation is a nonsense two 
base pair deletion which prematurely stops translation, leading to a smaller -catenin species (75 
kDa) [140].  In vitro studies of these mutants have shown increased wound healing and migration 
with both mutations, and decreased cell-cell adhesion with the Naxos mutation [141], indicating 
that the change in -catenin is affecting the cell junctions. Interestingly, both the diseases have an 
ARVC component; but very different etiologies. The ARVC mutant -catenin still localizes to 
the membranes, while the Naxos mutant -catenin does not, but instead localize to the nucleus 
[141]. This implies that -catenin mutations are detrimental in two ways: 1) affecting cell-cell 
adhesions; 2) extra-junctional influences. 
1.8.2 Cancer 
The role of -catenin in cancer is highly debated in the literature, especially the assignment its 
role as a strict tumor suppressor or oncogene. There are many instances of epithelial cancers in 
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which -catenin has unexplained aberrant expression and localization, including: breast [142, 
143], prostate [144], cervical [145], pancreatic [146, 147], colorectal [148-150], urothelial [151], 
gastric [147], bladder [152-154], lung [155, 156], and liver cancers [157-159]. Whether the 
changes in -catenin expression in these cancers are detrimental or helpful to the cancer 
prognosis is unclear, and discrepancies in the literature are even apparent within cancers of the 
same tissue (see 1.9.1 for debate in HCC). Additionally, the etiology of -catenin changes in 
these cancers is not very clear. Loss of heterozygosity (LOH) has been documented in some 
familial breast and prostate cancer cohorts [144, 160, 161], and a few cases of gastric and 
prostate cancer with Ser28Leu missense mutation of -catenin have been described [144, 147]. 
However, the reason for -catenin‟s mislocalization cannot be explained in most instances by the 
aforementioned genetic alterations. 
The most convincing argument for -catenin as a tumor suppressor comes from its LOH 
in breast and prostate cancers [144, 160, 161]. However, other studies have indicated that 
unregulated expression of -catenin leads to an aberrant increase in effector genes such as c-Myc 
which are clearly oncogenic [135]. However, -catenin itself may not be the culprit in these 
cancers, but merely a manifestation of oncogenic changes in the cell-cell junctions. Alterations in 
the desmosomes and AJs are known to play a role in cancer [162]. When desmosomes and/or 
AJs are disrupted, these junctions not only release potential oncogenic proteins, but also affect 
the invasive and metastatic potential of those cancers, negatively effecting clinical outcomes. If 
this is the case, then -catenin and the intact desmosomes and AJs should be considered as tumor 
suppressors. Therefore, whether the changes of -catenin in these cancers is correlated with a 
change in the cell-cell junctions should be an important factor to analyze when considering the 
role of -catenin in cancer. 
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1.9 γ-CATENIN IN LIVER BIOLOGY AND PATHOBIOLOGY 
Not many studies have attempted to elucidate the role of -catenin in liver biology or 
pathobiology. This may be because -catenin‟s role in the liver has been over-shadowed by its 
close relative -catenin, since -catenin liver-specific knockout models are available and there 
are known -catenin mutations which predispose individuals to HCC and other liver diseases. 
Currently, there are no known -catenin mutations in HCC. It is necessary to identify the roles of 
-catenin that are distinct from -catenin in the liver homeostasis since it is apparent that the 
balance of these proteins influences one another. More importantly, -catenin may play an 
important role in the liver, especially when -catenin insults occur.-Catenin also plays a unique 
role in desmosomal adhesion; however, this aspect of liver biology has also been understudied. 
The desmosomes in the liver may be smaller and not as numerous as in other tissue types, but 
they are not absent [163]. Hence -catenin may have an important in liver biology that needs to 
be investigated.  
1.9.1 Hepatocellular carcinoma 
As expanded upon above (1.3.1), HCC is a major health burden in the United States. Successful 
treatment for this type of cancer is rare, and so the disease management regimen is primarily 
palliative at this point. Studies have shown that in addition to Wnt/-catenin signaling pathway 
mutations/aberrations, the levels of -catenin may also influence the initiation and progression of 
HCC. Unfortunately, the data available for -catenin expression in HCC is conflicting. Studies 
by Endo et al. indicate that increased γ-catenin expression correlates positively with HCC grade 
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(highest in poorly differentiated HCC) [157].Conversely, Zhai et al. have shown that HCC 
patients with under-expression of -catenin have a poor survival rate [158]. 
However, as with other types of cancer with mislocalized -catenin levels, it may not be 
the change in -catenin expression which determines HCC tumorgenicity, but how these changes 
affect the junctions which ultimately influences HCC outcome. The studies by Zhai et al. 
correlate the expression of catenins and E-cadherin with HCC prognosis in a patient. They saw 
that a decrease in -catenin/E-cadherin or -catenin/E-cadherin was the driving factor for poor 
clinical prognosis and survival rate in HCC patients [158]. Additionally, Cao et al. observed that 
in well/moderately differentiated HCC, <50% of tumor cells exhibited a decrease in junctional 
proteins (including -catenin). But in poorly differentiated HCC cases, over 50% of tumor cells 
and nearly 100% of cancer cells no longer expressed desmosomal and AJ components [159]. 
This data not only reinforces the importance of these anchoring junctions in HCC 
development/progression, but also highlights the importance of keeping these junctions intact 
while treating HCC as to not worsen the prognosis. However, the cause and effect relationship is 
still lacking, thus mandating in depth mechanistic studies.  
1.10 GOALS OF THIS WORK 
The current body of literature on β-catenin in liver-specific diseases has prompted researchers to 
begin to investigate targeting β-catenin therapeutically in diseases such as HCC. The following 
studies will help fill the gap in knowledge regarding the effects of therapeutically targeting β-
catenin with respect to its roles in cell-cell adhesions at the AJs. Specifically, we would like to 
know if decreasing the levels of β-catenin may have any unintended negative consequences 
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which might affect the efficacy of the proposed therapies. Additionally, in light of only a subtle 
phenotype in mice lacking β-catenin in hepatocytes, we propose to determine the impact of its 
loss not only on the AJs and Wnt signaling, but also on other cell-cell junctions. 
We identify γ-catenin to compensate for loss of β-catenin at the AJ in the liver [91] 
(Chapter 2). As a result of altered γ-catenin expression in mice lacking β-catenin, we also 
propose to determine the mechanism of how this up-regulation occurs after β-catenin loss or 
knockdown in the liver and also in HCC cells in order to highlight the differences or similarities 
in β- and γ-catenin regulation which may be important for future HCC therapies. Lastly, -
catenin and desmosomes have been understudied in liver pathobiology, despite clinical 
observations of their dysregulation in HCC (1.9.1) [157-159]. Therefore, we also want to 
determine whether the changes in -catenin with loss or downregulation of -catenin might affect 
the desmosomes in the liver and if -catenin alone may have any influence on HCC prognosis. In 
this way we will be able to make recommendations to clinicians regarding potential anti--
catenin therapies. Therefore, we hypothesize that γ-catenin is unable to fully compensate for β-
catenin suppression/loss in the liver in Wnt signaling; however, it is able to help preserve a 
functionally stable AJ and thus maintain liver homeostasis. 
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2.0  HEPATOCYTE γ-CATENIN COMPENSATES FOR CONDITIONALLY 
DELETED β-CATENIN AT ADHERENS JUNCTIONS 
The major goal of the studies presented in this chapter was to understand the junctional 
reorganization of the AJs in the recently reported -catenin-conditional knockout mice (KO) 
generated by interbreeding transgenic mice homozygous for floxed--catenin gene (Ex1-6) and 
transgenic mice expressing Cre-recombinase under the Albumin promoter (see Methods 7.1.1) 
[34]. Here we identify an important compensatory role of -catenin (plakoglobin) at AJs in the 
KO livers. 
2.1 HEPATOCYTE-SPECIFIC β-CATENIN KNOCKOUT MOUSE (βKO) 
The hepatocyte-specific KO mice exhibit lower liver-weight-to-body-weight ratio, a marginal 
intrahepatic cholestasis and anomalous biliary canalicular architecture [164]. No gross defects in 
cell polarity or adhesion are evident in KO livers. Therefore, we wanted to explore the KO 
hepatic phenotype, or lack thereof, through identification of compensatory mechanisms in AJs, 
which enable the maintenance of a near normal liver histology in the absence of -catenin. 
To confirm genotype of the KO livers, -catenin levels were assessed. -Catenin protein 
was significantly decreased in the whole-cell lysates (WCL) and cytoskeletal-associated lysates 
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(CAL) of KO livers as compared to age- and sex-matched littermate wild-type controls (WT) 
(p<0.0005) (Figure 5A-B) (see section 7.7 for protein extraction details). Some remnant -
catenin expression was evident in KO livers; however, this was due to existence of -catenin in 
non-parenchymal cells unaffected by Albumin-Cre expression. Indeed, immunohistochemistry 
(IHC) and immunofluorescence (IF) in KO showed loss of membranous β-catenin in 
hepatocytes and cytoplasmic -catenin in cholangiocytes, whereas endothelial cells remained -
catenin-positive (Figure 5C-D). IP studies for -catenin were performed next. When blotted for 
E-cadherin, an epithelial-specific cadherin, the association between -catenin and E-cadherin 
was detected only in WT livers, confirming the loss of β-catenin in epithelial compartment 
(Figure 5E). From this data it is evident that -catenin is conditionally deleted from the 
parenchymal cells of the KO livers. 
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Figure 5. Assessment of -catenin in KO and WT livers.  (A) -Catenin (97 kDa) and GAPDH (as loading 
control; 37 kDa) protein levels in whole-cell lysates (WCL) and cytoskeletal-associated lysates (CAL) of three 
representative KO and age-and sex-matched WT livers by WB. (B) Normalized (to GAPDH) densitometric 
analysis reveals significantly lower (p < 0.05) average (± SD) -catenin protein expression in KO than WT livers 
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(n > 3). (C-D) Liver sections from KO and WT were analyzed for -catenin expression by IHC and IF. (E) WCLs 
were immunoprecipitated with anti--catenin antibody and probed for E-cadherin (120 kDa) by WB. 
2.2 CHANGES AT THE ADHERENS JUNCTIONS 
In adult liver, -catenin is chiefly observed at the hepatocyte membrane regulating cell-cell 
adhesion as a part of AJs and in the most perivenous hepatocytes displaying additional 
cytoplasmic and nuclear localization to regulate zonation [36]. Yet, conditional -catenin loss in 
hepatocytes resulted in a mild phenotype [34, 37]. To investigate changes in gene expression of 
AJ components, we analyzed microarray data from KO and WT livers [34]. Microarray 
analysis was performed as indicated in section 7.6.3. KO livers showed altered expression of α-
catenin (+2.4), E-cadherin (+2.6) and -catenin (+1.5) relative to WT (Table 1). WBs were 
performed to substantiate the array analysis. Insignificant differences in E-cadherin, -catenin 
and F-actin protein levels were observed in CAL and WCL from KO and WT livers (Figure 
6A). Interestingly, a significant increase in -catenin protein expression was observed in KO for 
both WCL and CAL lysates, despite no change in gene expression levels as assed via microarray 
analysis (Figure 6A-B; Table 1).  
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Table 1. Gene expression changes of junctional protein components in βKO livers. 
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Figure 6. Quantitative analysis of AJ proteins in KO and WT livers. (A) E-cadherin, -catenin (83 kDa), -
catenin (100 kDa), and F-actin (42 kDa) protein levels were detected in WCL and CAL of KO and WT livers by 
WB. WB for GAPDH verified comparable loading. (B) Normalized (to GAPDH) densitometric analysis reveals 
significantly higher (p <0.05) average (± SD) protein expression of -catenin in KO than WT livers (n > 3), while 
other proteins showed insignificant differences between the two groups. 
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IP studies were performed next to see if -catenin loss impacts association between AJ 
proteins. When E-cadherin was immunoprecipitated in WT and KO liver lysates, -catenin 
association was detected only in WT (Figure 7A), as in Figure 5A. We could not detect -
catenin association with E-cadherin in WT or KO livers (data not shown). Interestingly, -
catenin invariably associated with E-cadherin in KO while it was only minimally evident in 
complex with E-cadherin in the WT livers (Figure 7A). Conversely, when -catenin was 
immunoprecipitated in WT and KO livers, an association with E-cadherin was detected in KO 
livers only (Figure 7A). We also detected F-actin association with E-cadherin by IP in both WT 
and KO livers in the same complex. Thus, an intact connection of E-cadherin to actin 
cytoskeleton is maintained in WT and KO livers, albeit through -catenin and not -catenin in 
the latter. Lastly, IF studies were utilized to show co-localization of E-cadherin and -catenin 
only at the hepatocyte membrane of KO and not in WT livers (Figure 7B). From this data it is 
evident that -catenin associates with E-cadherin and F-actin in lieu of -catenin when -catenin 
is conditionally deleted from the parenchymal cells of the mouse livers. 
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Figure 7. Increase -catenin at the AJs ofKO hepatocytes. (A) WCLs were immunoprecipitated with anti-E-
cadherin or anti--catenin antibodies. (Upper panel) WB performed for -catenin, -catenin, and F-Actin show 
differential co-precipitation of -catenin and F-actin with E-cadherin in WT or -catenin and F-actin and E-cadherin 
in KO livers. (Lower panel) The conditions were reversed to show that -catenin also co-precipitates with E-
cadherin in KO. (B) Increased membranous -catenin (green) associates with E-cadherin (red), prominently in the 
KO hepatocytes as shown by representative double IF utilizing liver sections from KO and WT animals. 
2.3 LACK OF NUCLEAR γ-CATENIN DURING HEPATOCYTE PROLIFERATION 
-Catenin is a major component of the Wnt signaling pathway, where it translocates to the 
nucleus to increase target gene expression. However, aberrant activation of -catenin due to 
mutations in the Ctnnb1 gene, or components of its destruction complex such as Axin, results in 
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stabilization and nuclear translocation of -catenin that induces target genes critical to tumor 
growth and survival [10, 59]. Here we address whether -catenin can substitute for -catenin in 
hepatocyte Wnt signaling. 
Previously, others and we have reported a delay in liver regeneration after partial-
hepatectomy in KO mice such that peak hepatocyte proliferation was evident at 72 instead of 
40 hours [34, 40]. We hypothesized that if -catenin was compensating for nuclear -catenin 
function to induce hepatocyte proliferation, KO livers might show evidence of nuclear -catenin 
at 40 or 72 hours after hepatectomy. Partial hepatectomies were performed as indicated in 
section 7.2.1. IF studies detected -catenin only at hepatocyte membranes and not nuclei at either 
40 or 72 hours after hepatectomy in either group (Figure 8). As expected, IHC for Ki-67 on 
corresponding sections reveal hepatocytes in S-phase of cell cycle in WT at 40 and KO at 72 
hours (Figure 8). From this data it is evident that there is alack of nuclear -catenin during 
hepatocyte proliferation in absence of β-catenin.  Thus, -catenin is unlikely compensating for 
nuclear -catenin function in the liver. 
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Figure 8. Sustained membranous localization of -catenin in WT and KO livers during liver regeneration. 
While an increase in membrane signal of -catenin (green) is evident in KO as compared to WT, it was only 
localized to hepatocyte membrane at both 40 and 72 h after partial hepatectomy via IF staining, when several Ki-67 
positive hepatocytes are observed in WT and KO livers via IHC, respectively. No signal is detected in negative 
control when primary antibody is omitted in the reaction (inset, upper left panel). 
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2.4 MECHANISM OF γ-CATENIN STABILIZATION IN VIVO 
Here we begin to address the mechanism of -catenin increase in KO. For additional validation 
of microarray analysis, which revealed an insignificant increase in -catenin (Jup) gene 
expression (Table 1), we performed real-time PCR on KO and WT livers (see section 7.6.2 and 
Table 4 for real-time PCR details and primers respectively). CT values confirmed 
insignificant differences in Jup expression between KO and WT livers in three independent 
experiments (Figure 9A).  
We next assessed the phosphorylation status of -catenin in each condition. IP studies 
using -catenin antibody, identified greater serine and threonine phosphorylation of -catenin in 
KO mice when compared to WT (Figure 9B). No differences were observed in tyrosine-
phosphorylation of -catenin. Thus, increase in -catenin protein in KO livers coincide with a 
greater serine and threonine phosphorylation. From this data it is evident that the increase in -
catenin appears to be regulated by post-translational modifications in KO livers. 
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Figure 9. Mechanism of increased -catenin in KO livers. (A) Real-time PCR shown for -catenin gene (Jup) 
and cyclophilin-A (Ppia) reference gene shows insignificant difference in average mRNA expression (± SD) in KO 
versus WT livers (n = 3). Similar results were obtained for all Jup and reference gene primer combinations. (B) 
WCLs immunoprecipitated with anti--catenin antibody and western blotted for anti-phosphotyrosine, anti-
phosphoserine, or anti-phosphothreonine show greater serine and threonine phosphorylation of -catenin in KO 
livers as compared to WT, with no change in tyrosine phosphorylation. 
2.5 DISCUSSION: γ-CATENIN COMPENSATION FOR β-CATENIN LOSS AT 
ADHERENS JUNCTIONS 
We observed previously that hepatic architecture was well maintained in KO livers without any 
histological evidence of adhesion defect despite -catenin being a critical component of AJ [34]. 
Here, -catenin was identified to compensate for -catenin loss to maintain AJ in KO. -Catenin 
is highly homologous to β-catenin [111], and it is a unique component of desmosomes, [165]. 
Unlike the above paradigm however, in -catenin knockout mice, -catenin, despite its presence 
at desmosomes, was insufficient to functionally compensate for -catenin, causing embryonic 
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lethality due to faulty desmosomes [107]. In normal liver, we found a significant association of 
-catenin and E-cadherin, but not of -catenin and E-cadherin, suggesting the former complex to 
be a major contributor of hepatocyte AJs. Based on their nearly identical interactions with E-
cadherin [111], it is conceivable that during steady state, these two catenins may be competing to 
bind E-cadherin and their relative levels may eventually determine their relative contribution to 
AJ. Our studies demonstrate that -catenin is the predominant catenin in hepatocytes and thus 
the major form associating with E-cadherin. Indeed, increased levels of -catenin are known to 
displace -catenin from AJ [128]. On the other hand, in the absence of -catenin, -catenin is the 
clear „winner‟. In fact, an intact E-cadherin/-catenin/F-actin ternary complex was evident in 
KO livers in lieu of E-cadherin/-catenin/F-actin in the WT (Figure 7A). A similar 
compensation by -catenin for -catenin loss was recently reported to maintain normal 
cardiomyocyte structure and function as well [119]. 
The other components of AJ remained only minimally affected. There was an 
insignificant, albeit consistent, decrease in E-cadherin and -catenin proteins in KO. For AJ 
assembly, E-cadherin/-catenin complex forms in the endoplasmic reticulum and guides E-
cadherin to the plasma membrane [166]. This complex prevents exposure of the E-cadherin 
PEST domain for recognition by the proteasomal degradation machinery [26]. It is conceivable, 
that loss of -catenin may contribute to mild E-cadherin destabilization. However, as -catenin 
binds to E-cadherin identically [111], it is likely that excess degradation of E-cadherin is 
prevented. An increase in E-cadherin and -catenin gene expression might be compensatory due 
to decreased proteins. We were unable to detect -catenin in complex with E-cadherin in WT or 
KO livers. Recent studies have provided evidence that -catenin and -catenin interactions 
with F-actin might be mutually exclusive [167]. In our study we detect ternary complexes 
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composed of E-cadherin/-catenin/F-actin in the WT or E-cadherin/-catenin/F-actin in the KO 
livers.  
-Catenin has also been shown to function as a downstream effector of the canonical Wnt 
pathway, translocating to the nucleus and regulating target gene expression, as reported in 
malignant mesothelioma (epithelial) cells albeit upon complete β-catenin loss [127]. -Catenin 
contains armadillo repeats, which weakly interact with TCF/LEF, regulating distinct Wnt 
signaling [122, 123]. At baseline, no nuclear -catenin is observed in the KO livers. Lack of 
nuclear compensation is also supported by absence in the KO of -catenin transcriptional 
targets such as Glutamine Synthetase, CYP2E1 and CYP1A2, leading to defects in zonation, 
ammonia metabolism and xenobiotic metabolism [34, 36, 37, 168]. Similarly, regenerating livers 
at 40 and 72 hours after hepatectomy (times of peak hepatocyte proliferation in control and KO 
livers respectively) [34, 40], do not show any nuclear -catenin also arguing against nuclear 
compensation in absence of -catenin. 
Here we observed that the protein levels of -catenin were disproportionately greater than 
its gene expression suggesting post-translational regulation. We identified increased serine and 
threonine phosphorylation of -catenin in KO livers along with greater -catenin-E-cadherin 
association. Changes in phosphorylation status of -catenin leading to its stabilization and altered 
subcellular localization have been reported previously [115]. Additional characterization to 
determine signaling mechanisms regulating -catenin phosphorylation and its impact on 
association with E-cadherin can be found in Chapter 6.  
β-Catenin activation due to multiple causes occurs in significant subsets of HCC [3, 46]. 
While -catenin is no doubt a therapeutic target, it remains unclear what impact -catenin 
inhibition might have on the integrity of AJ and ultimately on tumor cell invasion and metastasis. 
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From our current study, it appears that while -catenin nuclear functions, which are more critical 
for tumor cell survival and proliferation, may not be compensated, its functions at the AJ are 
effectively substituted by -catenin. Such pathways that may induce -catenin stabilization may 
need to be spared during anti--catenin therapies for cancer treatment to prevent concurrent -
catenin suppression that may inadvertently increase tumor cell invasion. 
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3.0  EFFECT OF γ-CATENIN STABILIZATION ON OTHER HEPATOCYTE 
JUNCTIONS 
As previously discussed, the chronic loss of hepatocyte -catenin in our KO mice resulted in 
only a mild liver phenotype of: lower liver-weight-to-body-weight ratio, mild intrahepatic 
cholestasis, and irregular biliary canalicular architecture [34, 41]. Additionally, there were no 
gross defects in cell polarity or adhesion which manifested in KO livers with or without 
challenges (partial hepatectomy, DDC diet, DEN injection, phenobarbital, or methionine- and 
choline-deficient (MCD) diet [34, 41, 42, 169, 170]). This was surprising, given that -catenin is 
a major component of the AJ in the liver. Initially, we observed that -catenin was compensating 
at the AJs with -catenin loss (Chapter 2) [91]. However, -catenin is a major protein 
component of the desmosomes. Additionally, we observed the loss of -catenin target genes in 
our KO mice, which included known TJ components (claudin-2) [34]. Therefore, to further 
expand upon the KO junctional phenotype, or lack thereof, we decided to investigate 
compensatory changes in other hepatocyte anchoring and occluding junctions in addition to the 
changes previously noted for the AJs (Chapter 2). Here we identify no changes in hepatocyte 
desmosomes, despite the increase of desmosomal protein -catenin at the AJs. Additionally, we 
see compensatory changes in hepatocyte tight junctions (TJs) with the rearrangement of AJs as a 
result of junctional cross-talk. 
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3.1 DESMOSOMES 
3.1.1 Hepatocyte desmosomes remain intact with β-catenin loss and γ-catenin increase at 
adherens junctions 
It has been previously shown by our lab and others that -catenin is able to compensate for -
catenin loss at the AJ by binding to E-cadherin [91, 113-119] (see also Chapter 2). This increase 
in -catenin is not at the transcriptional level, but appears to be a post-translational modification 
that stabilizes the protein and increases overall expression levels [91, 115, 171] (Figure 9A). 
However, -catenin is primarily a desmosomal protein, so is this AJ compensation for -catenin 
loss at the cost of desmosomal integrity? Initially we used transmission electron microscopy 
(TEM) to look for the presence of recognizable desmosomes in KO and age-and sex-matched 
WT livers. Here we see that in fact there are identifiable, and visibly identical desmosomes 
present in both KO and WT livers (Figure 10A). Quantification of the hepatocyte desmosomes 
revealed no significant difference in intercellular distances at these junctional interfaces, with 
mean distances of 27.4 nm in the KOs and 25.1 nm in the WTs (p>0.10) (Figure 10B). 
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Figure 10. -Catenin increase in the KO mice does not deplete hepatocyte desmosomes. (A) Transmission 
Electron Microscopy analysis of -catenin KO and WT livers show the presence of desmosomes (arrows).  (B) The 
intercellular distance between hepatocytes connected by desmosomes are not significantly different (mean distances 
KO=27.4 nm, WT=25.1 nm, p > 0.05). 
 
 
Next, to investigate gene expression changes in desmosomal components, we analyzed 
microarray data from KO and WT livers [34]. KO livers showed altered expression of 
desmocollin-2 (+2.2 fold), desmocollin-3 (+3.8 fold), and plakophilin-3 (-3.7 fold) (Table 1). 
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Interestingly, desmocollin-3 has never been shown to be present in the desmosomes of the livers, 
but we see a robust increase in mRNA expression in the KO livers [159]. Desmocollin-3 is a 
key desmosomal cadherin, especially in stratified epithelia, and loss of this protein in the mouse 
results in K-Ras-induced skin tumors [172]. 
Since changes in mRNA levels do not always correspond to overall protein levels, 
especially with catenins and cadherins [91], we wanted to further analyze the protein expression 
of liver-specific desmosomal proteins [64]. We analyzed Triton X-100 soluble (S) and insoluble 
(I) cytoskeletal-associated (CAL) fractions of -catenin KO and WT livers for desmosomal 
protein expression by WB. We confirmed that there was an increase in -catenin levels in the 
KO livers (Figure 11B). This increase in -catenin was in both S- and I-fractions, but the most 
notable change was the appearance of cytoplasmic/S-fraction -catenin only with -catenin loss 
(Figure 11B). Next, we evaluated the levels of desmoplakin I and II (DPI/II), desmoglein-1 
(Dsg1), Dsg2, Dsg3, Dsg4, desmocollin-2 (Dsc2), and plakophilin-2 (Pkp2), and there was no 
change in overall protein levels of these proteins, despite changes in some mRNA levels (Figure 
11A; Table 1). Interestingly, the only desmosomal protein that was changed was Pkp3, which 
was up-regulated in both the S- and I-fractions (Figure 12A), despite a -3.7 fold decrease in 
mRNA expression (Table 1). 
Despite the similarities in protein levels of most desmosomal proteins analyzed, we 
wanted to see if there was a change in desmosomal protein association with -catenin. Here we 
show via immunoprecipitation that there was no change in DPI/II, Dsg1, Dsg2 (data not shown), 
and Dsg4 association with -catenin between KO and WT livers in I-fraction (Figure 11C) and 
S-fraction lysates (data not shown). In summary, the lack of ultrastructural changes, along with 
minimal changes in various desmosomal proteins, and a lack of changes in -catenin‟s 
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interactions with various desmosomal proteins support the notion that the increase in -catenin 
due to -catenin loss is not at the expense of the molecular configuration of the desmosomes. 
 
 
 
Figure 11. KO mouse livers show no changes in desmosomal proteins, except plakophilin-3. (A) -Catenin 
KO livers have no apparent changes in most desmosomal protein levels in S and I CAL fractions via WB, despite 
some  mRNA changes (Table 1): DPI (250 kDa), DPII (210 kDa), Dsg1 (150 kDa), Dsg2 (59–150 kDa), Dsg3 (55–
130 kDa), Dsg4 (100–115 kDa), Dsc2 (110 kDa), and Pkp2 (100 kDa). However, Pkp3 (87 kDa) is slightly 
increased in KO livers in both in S and I CAL fractions over WT age-and sex-matched livers lysates. (B) -Catenin 
KO livers show more soluble and insoluble -catenin (83 kDa) than WT livers by WBs. WB for Actin (42 kDa) 
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verifies comparable loading. (C) Representative immunoprecipitations of -catenin in I-fraction shows no apparent 
changes in desmosomal protein associations with -catenin in KO and WT livers. (D) Pkp3 co-precipitates with -
catenin (upper panel) and E-cadherin (lower panel) equally in the S-fractions of KO and WT livers. (E) Nuclear 
lysates show Pkp3 protein levels are similar between KO and WT livers. 
3.1.2 Changes in plakophilin-3 with β-catenin loss with no apparent consequences on 
desmosomes 
Next, we wanted to address the Pkp3 increase in the KO livers. Initially, we investigated 
whether the species of Pkp3 that increased with -catenin loss had different binding partners 
which may affect Pkp3 trafficking in the cytoplasm. It was recently published that a complex of 
-catenin, E-cadherin and Pkp3 is required to initiate desmosome formation [108]. Since both -
catenin and Pkp3 are known binding partners, and both were increased with -catenin loss, we 
wanted to see if these proteins associated more readily in the KO livers, possibly contributing to 
their mutual stabilization. IP studies showed Pkp3 binding to both E-cadherin and -catenin in 
the S and I (not shown) CAL fractions, but there was no change in Pkp3 association with -
catenin loss (Figure 11D). This is in agreement with the lack of any changes the in overall 
desmosomal structure in KO mice (Figure 10A). To further investigate the possible reason for 
the increase in Pkp3 levels with -catenin loss, we wanted to see if the increase Pkp3 levels lead 
to increased nuclear Pkp3, since it has been shown to have potential nuclear functions [173]. 
Here we show that there was comparable nuclear Pkp3 in the KO and WT livers (Figure 11E). 
The changes in Pkp3 levels with -catenin loss cannot be explained by changes in cytoplasmic 
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binding partners or with nuclear localization. Therefore, additional studies will be necessary to 
address the role and regulation of Pkp3 after -catenin loss. 
3.2 TIGHT JUNCTIONS 
3.2.1 Hepatocyte tight junctions have compensatory changes with β-catenin loss at 
adherens junctions 
In epithelial cells, such as the hepatocytes of the liver, TJs are located between basolateral and 
apical domains of hepatocytes. These junctions contribute to paracellular adhesion, cell polarity 
and serve as occluding barriers around the biliary canaliculi [67, 174]. TJs are multiprotein 
complexes composed chiefly of claudins, junctional adhesion molecules (JAM) and occludin 
[175] (See 1.4.2). Anomalies in TJ have been associated with an imperfect blood-bile barrier and 
also implicated in various hepatic pathologies, namely cholestasis [176, 177]. A cross-talk 
between AJ and TJ, and among other plasma domains has been reported [79]. Additionally, AJ 
proteins can influence the expression of TJ proteins [178]. 
Based on the observed cross-talk between the components of AJ and TJ [69], we 
analyzed KO and WT livers for any alterations in gene expression of TJ components by 
microarray. KO livers showed altered expression of claudin-1 (–2.3), claudin-2 (–8.0) and 
JAM-A (–2.0) but insignificant changes in the expression of claudin-3, occludin, ZO-2 or ZO-1 
(Table 1). By WB, we assessed WCLs from WT and KO livers for TJ proteins. Despite 
decreases in gene expression, JAM-A and claudin-1 protein levels were significantly elevated in 
KO (Figure 12A-B). However, concordant with lower gene expression, a significant decrease 
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in claudin-2 protein was observed in KO (Table 1; Figure 12A-B). Insignificant differences in 
occludin and claudin-3 levels were evident, which was in accordance with the microarray data 
(Figure 12A-B and [164]; Table 1). 
3.2.2 Compensatory changes in hepatocyte junctions does not cause leaky tight junctions 
Follow-up studies on TJ ultrastructure and function were performed in the lab of Dr. Jai Behari 
at the University of Pittsburgh, Department of Medicine in collaboration with the Center for 
Biological Imaging and Dr. Satdarshan P.S. Monga (published in Hepatology in 2010 [164]).  To 
determine if the changes in JAM-A, claudin-1 and claudin-2, negatively affected the structure of 
the TJ, the Behari lab looked for the formation of TJs via TEM. There were no distinguishable 
changes in the ultrastructure of the TJs surrounding the bile canaliculi in the KO livers [164]. 
Next, to test the functionality of the hepatic TJs, the integrity of the blood-bile barrier was tested 
by measuring the leakage of FITC-conjugated dextran (FC-40) from the blood into the bile (see 
[164] for experimental details). If the KO TJs were compromised, and leakier, as a result of the 
changes in the claudin and JAM expressions, then we would have expected a peak in the FC-40 
in the bile of the KO to occur before that of the WT mice. However, the Behari lab‟s 
assessment of the hepatic TJs showed a delay and decrease in the KO FC-40 peak [164]. 
Interestingly, it appears that the KO TJs are “tighter” than the WT junctions. 
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Figure 12. KO mouse livers show compensatory changes in tight junction. (A) Examination of TJ protein 
expression by WBs using WCLs shows an increase in JAM-A (35 kDa) and claudin-1 (22 kDa), no change in 
occludin (60-82 kDa) and absence of claudin-2 (22 kDa) in KO livers. GAPDH served as the loading control. (B) 
Normalized (to GAPDH) densitometric analysis reveals significantly (*p < 0.05) lower average (± SD) protein 
expression of claudin-2 and higher average (± SD) expression of JAM-A and claudin-1 in KO than WT livers (n > 
3), while occluding remained unchanged. 
3.3 DISCUSSION: HEPATOCYTE JUNCTIONS 
It was important to initially address the influence of -catenin changes with -catenin loss on the 
desmosomes, especially since the trafficking of -catenin to the AJ is controlled post-
transcriptionally [91, 115, 171]. Additionally, disruptions in desmosomes have been shown to 
play a role in cancer progression [159, 179, 180], and thus compensation by -catenin at AJs may 
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come at the expense of desmosomal integrity, which may have indirect and unintended negative 
side effects upon -catenin therapeutic targeting in HCC. We have previously shown using a 
hepatocyte-specific -catenin KO mouse that -catenin is increased and compensating for -
catenin loss at AJ by complexing with E-cadherin [91]. We now show that such compensation 
does not have any functional consequences on desmosomal structure in the liver. This was 
confirmed in multiple ways, including the observation that the -catenin/E-cadherin/Pkp3 
cytoplasmic complex, which has been shown to be important for desmosomal assembly [108], 
was unchanged in KO mice. We also show the structure of desmosomes was not affected in 
vivo via TEM. We did however see an increase in Pkp3, but are unable to explain the 
significance of this increase at this time. We speculate that Pkp3 increase after -catenin loss 
may be more directly related to the changes in Wnt signaling than changes in AJ, in the same 
way claudin-2 levels are changed in KO mice since we did not see changes in Pkp3 localization 
via co-precipitations or nuclear lysates. This observation still remains under scrutiny in our lab. 
We also identify changes in protein expression of various TJ components in the absence 
of -catenin. TJ are a set of multi-protein complexes that contribute to cell-cell adhesion, 
polarity, segregating various domains of the hepatocytes, enabling proper hepatocyte secretory 
function [67, 79]. Claudin-2 was absent in KO livers. This is not surprising since it is a known 
Wnt target gene [178] and we also reported its downregulation in KO livers previously [34]. 
While gene expression of JAM-A and claudin-1 were decreased in the KO livers, their protein 
levels were increased, suggesting a post-transcriptional regulation. Interestingly, despite these 
changes, our collaborators reported lack of any major functional defect in the integrity of hepatic 
TJ in KO mice by assaying for biliary excretion of FITC-conjugated dextran after intravenous 
injection [164]. It is conceivable that loss of claudin-2 may be compensated by claudin-1 and in 
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fact result in tighter TJ, since claudin-2 expression is usually contributes to leakiness in epithelia 
while claudin-1 does not [92, 181, 182]. However, claudin-1 compensation for the absence of 
claudin-2 may also be imperfect since the former is a barrier forming while the latter is a pore 
forming claudin. Additionally, changes in JAM-A might also have a compensatory impact on 
maintaining TJ in absence of claudin-2 and -catenin. However, both of these hypotheses will 
need to be confirmed. 
While the notion of cross-talk between TJ and AJ exists, a recent study for the first time 
showed an inverse relationship between E-cadherin and JAM-A in HCC cells [69]. Based on our 
observations, we suggest that -catenin/claudin-2 may be another important means of cross-talk 
between AJ and TJ through which aberrations in one junction may be transmitted to the other 
through both structural and signaling cues. It is yet untested whether this particular cross-talk 
node is universally recognized, or whether this may be a function of HCC pathogenesis. 
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4.0  SPONTANEOUS REPOPULATION OF β-CATENIN-NULL LIVERS WITH β-
CATENIN-POSITIVE HEPATOCYTES AFTER CHRONIC LIVER INJURY 
Chronic exposure to 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC), a porphyringenic drug, 
results in hepatobiliary injury, atypical ductular proliferation (ADP), appearance of hepatic 
progenitor cells (A6-positive oval cells), and limited fibrosis. The etiology of this xenobiotic is 
aberrant secretion of porphyrin from the biliary tract which leads to the formation of porphyrin 
crystal plugs in the bile ducts [183]. Obstruction of the bile ducts leads to slowed bile flow, a rise 
in serum bilirubin, and ultimately interhepatic cholestasis.  
Oval cells are the putative adult stem cells of the liver. They are considered facultative 
stem cells which usually appear in response to hepatobiliary injury, especially when hepatocyte 
proliferation is simultaneously blocked; specifically, this oval cell response occurs with specific 
xenobiotics, such as DDC, Dipin, and high-fat diet + ethanol [65]. Oval cell activation induces 
ADP, which is pathologically manifested as an increase in biliary ductules, leukocyte infiltration, 
and an increase in extracellular matrix components [184]. Chronic ADP eventually leads to 
periportal and biliary fibrosis. This ductular reaction is known to be a part of cholestatic disease 
etiologies. Additionally, the chronic activation/appearance of oval cells has also been linked to 
the induction of liver cancer [65, 185], which raises the possibility that oval cells could also be 
cancer stem cells. 
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Recently, our lab has shown that these oval cells co-stain with -catenin [186]. 
Additionally, our lab demonstrated that there was a blunted oval cell response with loss of -
catenin and acute DDC exposure (under 24 days) [186]. Therefore, we were interested in 
expanding upon these results to identify the role of -catenin in chronic DDC exposure. Chronic 
DDC exposure is known to lead to unresolved ADP, and liver injury that eventually resembles 
primary sclerosing cholangitis (PSC). Here we show that as with the acute DDC exposure, 
chronic exposure (80-150 days) to DDC lead to ADP and A6-positive oval cell infiltration, but 
this time it was to a greater extent in KO livers (data previously published by Thompson et al., 
2011 [169]). Additionally, there was a surprising amelioration of hepatocyte injury at later time 
points in the KO mice, which coincided with spontaneous -catenin-positive hepatocyte 
repopulation of the -catenin-null livers. 
4.1 GREATER BILIARY INJURY BUT ONLY MODEST HEPATOCYTE INJURY 
IN βKO MICE ON DDC DIET 
Gross analysis of the DDC livers showed that the KO livers were enlarged, with macroscopic 
non-cancerous nodules after 150 days. Because of the additional weight of the nodules, the liver-
weight-to-body-weight ratio of the KO mice was equal to the WT mice. To try and address the 
etiology of the hepatic nodules, trichrome staining was performed to assess fibrotic load. The 
KO livers had a greater degree of fibrosis, especially between portal triads at 150 days on DDC 
diet as compared to the WT mice (data previously published by Thompson et al., 2011 [169]). 
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To further assess the extent of hepatic/biliary injury, serum biochemistry analysis was 
performed to test the levels of total bilirubin, alkaline phosphatase, AST, and ALTs in the blood 
of WT and KO mice on DDC diet for 80 and 150 days. High bilirubin and/or alkaline 
phosphatase levels indicate cholestasis while ASTs and ALTs are good indications of hepatic 
damage. The liver function tests for mice on long-term DDC diet showed that the KO mice had 
significantly higher serum bilirubin at 80 days and alkaline phosphatase levels at 150 days, 
indicating increase intrahepatic cholestasis and biliary injury over WT mice [169]. Conversely 
ALTs were significantly higher in the WT at 80 and 150 days [169], which was unexpected. 
Interestingly, these results indicate that the KO mice had less hepatocyte injury than the WT 
mice on DDC diet, despite increase in ADP (data previously published by Thompson et al., 2011 
[169]). 
4.2 PROGRESSIVE REPOPULATION OF βKO LIVERS ON DDC DIET WITH β-
CATENIN-POSITIVE HEPATOCYTES 
We next wanted address why the KO mice had diminished hepatocyte injury after long term 
DDC feeding as compared to the WT mice. To our surprise, IHC analysis of the KO livers 
showed that these -catenin-null livers were expressing -catenin-positive hepatocytes (Figure 
13A), and had re-expression of -catenin that was also apparent via WB analysis after 150 days 
of DDC diet (Figure 13D). It was imperative for our analysis to determine the chronology of this 
repopulation; therefore, we looked at KO livers on DDC diet at times before 30 and 80 days, 
when we see small -catenin-positive clusters, to see if we could find when single -catenin-
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positive hepatocytes arise. At 7 days on DDC diet, we were able to find singular -catenin-
positive hepatocytes in the KO livers via IF (Figure 13B). These -catenin-positive 
hepatocytes were located periportally, but did not co-localize with the A6-positive cells (Figure 
13B). Additionally, these -catenin-positive cells stained for epithelial- (E-cadherin) and 
hepatocyte-specific (CCAAT-enhancer-binding protein  - CEBP) markers (data previously 
published by Thompson et al., 2011 [169]). Further analysis of KO livers via IHC showed that 
-catenin-positive biliary cells did not begin to appear until at least 80 days of DDC exposure 
(Figure 13C). As we previously reported, KO mice showed that despite a hepatocyte-
targeted/Albumin-Cre driven deletion of -catenin, there was a lack of normal -catenin 
expression in the bile ducts of these mice [34] (Figure 13C), possibly because of the shared 
hepatoblast origin of hepatocytes and cholangiocytes.  Taken together, this data indicates that the 
-catenin-positive hepatocytes most likely did not originate from the oval cells, since -catenin-
positive hepatocytes precede the appearance of -catenin-positive bile ducts in the KO livers. 
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Figure 13. Progressive repopulation of KO livers on DDC diet with -catenin-positive hepatocytes. (A) IHC 
staining of KO livers after 30, 80 and 150 days on DDC diet show -catenin-positive hepatocytes (arrowheads). 
Images shown are at 200x magnification. (B) Double IF staining for A6 (green) and -catenin (red; arrowheads) 
shows no co-localization of these markers at baseline and in KO livers after short and long-term DDC diet. Images 
shown are at 200x magnification. (C) IHC staining for -catenin after 80 days of DDC diet shows strong expression 
of -catenin in atypical ductular cells in WT (black arrows) and lack thereof in KO liver (white arrows) even 
within newly developed clusters of -catenin-positive hepatocytes (red arrow). However, some -catenin-positive 
duct cells (black arrow) do appear, whereas others remain negative (white arrow) amid -catenin-positive 
hepatocytes (red arrow) at 80 and 150 days on DDC diet. Images shown are at 400x magnification. (D) WB analysis 
 64 
of -catenin, its downstream targets (GS, cyclinD1), and hepatocyte-specific markers (HNF4). WB for Actin 
verifies comparable loading. Data previously published by Thompson et al., 2011 [169]. 
4.3 PROGRESSIVE REPOPULATION OF βKO LIVERS ON REGULAR CHOW 
DIET WITH β-CATENIN-POSITIVE HEPATOCYTES 
It is possible that there were -catenin-positive hepatocytes in the livers before DDC exposure. 
This led us to analyze baseline KO livers on regular chow at different ages. Surprisingly at 
three months of age around 1-2 hepatocytes per 200x magnification were -catenin-positive in 
the KO livers as detected by IF (Figure 13B). As an additional control, livers from 5 to 8-
month-old mice were assessed for degree of spontaneous repopulation with -catenin-positive 
hepatocytes without any DDC exposure by IF (n = 6) and IHC (n = 5). By IF, four KO livers 
showed less than 1% -catenin-positive hepatocytes, whereas two KO livers had around 20%-
30% spontaneous repopulation (Figure 14). Five additional KO livers showed less than 1% 
hepatocytes to be -catenin-positive in the KO by IHC as well (data not shown). Thus, a 
majority of the KO livers did not show many -catenin-positive hepatocytes at baseline, 
suggesting only a DDC injury-dependent spontaneous repopulation with -catenin-positive 
hepatocytes, which may have initially escaped Albumin-Cre driven -catenin deletion. However, 
a very small subset of KO livers did show the presence of greater numbers of -catenin-positive 
cells for unknown reasons, albeit nowhere to the extent observed after DDC exposure. 
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Figure 14. Progressive repopulation of KO livers on regular chow diet with -catenin-positive hepatocytes. 
IF showing -catenin-positive hepatocytes in WT liver and three KO livers at baseline. Although two livers 
represent a common phenotype of a few -catenin-positive hepatocytes in KO, one liver was an exception and 
showed greater repopulation (right-most panel). Images are shown at 100x magnification. 
4.4 β-CATENIN-POSITIVE HEPATOCYTES DO NOT EXPRESS HEPATIC STEM 
CELL MARKERS 
We also examined the status of the -catenin-positive cells for some known markers of hepatic 
progenitors. In KO livers at baseline, none of the -catenin-positive cells were positive for 
commonly used markers of oval cells such as Ep-CAM, Cd133 or LGR5 (Figure 15). 
Interestingly, in the KO livers occasional -catenin-positive hepatocytes were -fetoprotein-
positive (AFP) as were a few non--catenin-positive hepatocytes (Figure 15). Thus, this analysis 
suggests that -catenin-positive cells in the KO livers are mostly mature hepatocytes, which 
amid chronic insult due to chronic DDC exposure may display growth and survival advantage to 
gradually repopulate the KO liver. 
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Figure 15. -Catenin-positive hepatocytes in KO livers do not express hepatic progenitor markers. There was 
no co-localization in the KO livers of -catenin (red) with Cd133, Ep-CAM, or LGR5 (green), whereas the positive 
controls showed positive signal in DDC liver or small intestine (right column). In addition, some -catenin-positive 
cells (red) were positive for -fetoprotein (AFP; green), whereas some non--catenin-positive cells were also -
catenin-positive. Images shown are at 400x magnification. 
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4.5 PROGRESSIVE LOSS OF CRE-RECOMBINASE IN βKO LIVERS ON DDC 
DIET 
Lastly, we were interested in the mechanism of the -catenin repopulation of the KO livers. We 
hypothesized that the -catenin positive cells must have somehow escaped the influence of Cre-
recombinase. To examine whether the increase in the number of -catenin-positive hepatocytes 
correlates with a decrease in expression of the transgene, we performed real-time PCR analysis 
for Cre-recombinase at 30, 80, and 150 days after DDC feeding. Real-time PCR analysis was 
performed for Cre-recombinase in three separate mouse livers using three different reference 
genes. The analysis showed that there was no significant difference in mRNA expression of Cre-
recombinase between untreated age- and sex-matched KO mouse livers and the 30 days DDC-
fed KO livers (data not shown). However, between 30 and 80 days after being on the DDC diet, 
there was a significant decrease in Cre-recombinase expression (p = 0.00043) (Figure 16). This 
expression continued to significantly decrease with ongoing DDC exposure (30 to 150 days on 
DDC, p = 0.00005; 80 to 150 days on DDC, p = 0.091). Thus, this analysis suggests repopulation 
of the KO liver after long-term DDC feeding is by hepatocytes, which have escaped expression 
of the Cre-recombinase transgene. 
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Figure 16. Progressive loss of Cre-recombinase expression in KO livers on long-term DDC diet. Cre-
recombinase mRNA expression in KO mice at 30, 80, and 150 days after DDC diet shows a progressive and 
significant decrease (*p < 0.1; **p < 0.001). mRNA expression values were normalized to cyclophilin-A (Ppia) as a 
reference gene. Bars show +/- SD values of triplicate readings. 
4.6 β- AND γ-CATENIN ARE MUTUALLY EXCLUSIVE AT HEPATOCYTE 
ADHERENS JUNCTIONS 
As reported here by our lab, and also recently by other labs, the Albumin-Cre/Lox system of 
knocking out genes in hepatocytes may sometimes be “leaky,” especially after about six months 
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of age, causing some repopulation of KO livers with -catenin positive hepatocytes [43, 169]. 
We used this anomaly as a proof-of-concept for the work on “Hepatocyte -catenin compensates 
for conditionally deleted -catenin at AJs” (Chapter 2). We performed immunofluorescence 
staining on liver sections of an 8 month old KO mice (on regular chow) to assess the 
localization of - and -catenin at the membrane of hepatocytes with and without -catenin. We 
previously showed conditionally deleted KO mice had an increase in -catenin co-localization 
with E-cadherin at the AJ where -catenin is normally located (Figure 7B). Here we see that in a 
mosaic -catenin-positive/-catenin-negative liver section that -catenin (red) and -catenin 
(green) appear to be mutually exclusive at the hepatocyte membranes, with relatively no co-
localization (Figure 17).  Analysis of the -catenin localization in the -catenin positive nodule 
shows a desmosomal-like staining pattern, while -catenin localization in the remainder of the 
KO liver section has an AJ-like staining pattern (Figure 17: inset, green channel). 
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Figure 17. - and -Catenin are mutually exclusive at hepatocyte adherens junctions. Membranous -catenin 
(green channel) and -catenin (red) are mutually exclusive at the cell membranes / AJ of KO livers which become 
repopulated with -catenin-positive hepatocytes at elderly ages as shown by representative double IF images of 
fixed liver sections. Images shown are at 400x magnification. 
4.7 DISCUSSION: SPONTANEOUS REPOPULATION 
These studies were initiated after observations that there was a dampened A6-positive oval cells 
activation in KO mice following acute liver injury, indicating an important role of -catenin in 
oval cell activation and proliferation [186]. However, chronic DDC exposure actually led to a 
paradoxical increase in ADP and A6-positive oval cell infiltration in the KO mice, indicating 
that there was an initial delay in the KO mice that was not sustained after chronic hepatobiliary 
injury. Therefore, we also expected to see an increase in liver injury in the KO mice as well. 
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We did see a significant increase in bilirubin at 80 days and alkaline phosphatase at 150 days in 
the KO mice indicating increased biliary injury [169]. However, the KO mice had 
significantly lower serum AST and ALT levels, indicating only modest hepatocyte injury as 
compared to the WT mice [169]. Further investigation showed that this phenomenon was due to 
the unexpected spontaneous repopulation of the KO livers with -catenin-positive hepatocytes 
that had escaped the influence of Cre-recombinase. 
These events prompted us to look more critically at our KO mice. Much to our surprise, 
variable repopulation of the -catenin-null liver also occurred spontaneously without chronic 
injury, as we were able to detect -catenin-positive cells in a sub-population of older mice 
(Figure 14). This observation was made around the same time by other labs as well, highlighting 
the leakiness of the Albumin-driven Cre-LoxP system [43]. There is efficient deletion of -
catenin at two months of age in these animals, but as the mice age past four months there is 
appearance of a small population of -catenin-positive cells [34, 43]. Further analyses showed 
that -catenin-positive hepatocytes are mature hepatocytes, and do not involve the hepatic 
progenitor cells (Figure 15). It appears that the older mice are able to escape the influence of the 
Cre-recombinase [34] (Figure 16). Whether this is an artifact of liver-specific/Albumin-driven 
knockouts remains to be determined. As of now though, this model is still an effective tool for 
looking at hepatocyte-specific deletions of -catenin and other proteins, as long as the 
appropriately aged mice are used, and the caution of spontaneous repopulation is heeded and 
recognized in the assessment of data. 
Recently, it has been shown that mature hepatocytes have a unique capacity to increase 
and decrease their ploidy, which may be due to metabolic or xenobiotic insults which allows the 
hepatocytes to adapt and create a genetically diverse population of cells within the liver [187]. 
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Therefore, it is possible that the liver may have an innate ability to create a population of 
hepatocytes that are able to adjust better to chronic injury. This may be an explanation for the 
repopulation of -catenin-null livers, where the hepatocytes are able to elude the influence of 
Cre-recombinase in order to reintroduce -catenin into the liver. 
Despite unexpected realizations of the limitations of our in vivo conditional-knockout 
model, the repopulation of the -catenin-null livers with -catenin positive-hepatocytes has 
created a new and useful tool for our lab and others. We now have an in vivo model which has a 
mosaic expression of -catenin-positive and -null hepatocytes which can be utilized for other 
experiments. Recently, these mosaic knockout mice were helpful as a proof of concept of the 
results put forth in the manuscript “Hepatocyte -catenin compensates for conditionally deleted 
-catenin at adherens junctions” [91], showing that - and -catenin are mutually exclusive at 
hepatocyte AJs (Figure 17). Further characterization of the repopulated -catenin-null livers 
should serve as a useful tool in understanding not only for transgenic mouse models, but also 
general liver and hepatocyte physiology. 
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5.0  γ-CATENIN AT ADHERENS JUNCTIONS AFTER β-CATENIN LOSS: 
BIOLOGICAL IMPLICATIONS IN HEPATOCELLULAR CARCINOMA 
We have previously demonstrated that -catenin is increased at the AJs but not in the nucleus of 
KO mice with chronic -catenin loss (Chapter 2) and that this compensation of -catenin in 
KO mice does not come at the expense of desmosomal structure and integrity (Chapter 3). 
This data is encouraging for the idea of treating HCC with anti--catenin therapies. Therefore, 
we moved to a more easily manipulated in vitro model of -catenin knockdown in HCC cells in 
order to more comprehensively address the impact of -catenin loss on HCC cell physiology. 
Here we show in an in vitro model that -catenin alleviates -catenin loss at AJ in HCC cells to 
maintain cell-cell adhesion function, but is unable to fulfill its role as a component of the 
canonical Wnt signaling cascade.  
5.1 GENERATION OF IN VITRO MODEL OF β-CATENIN KNOCKDOWN IN 
HEP3B CELLS LEADS TO γ-CATENIN INCREASE 
Initially we observed that -catenin protein levels were significantly increased with the 
conditional hepatocyte -catenin knockout in vivo in 60 to 120 day-old mice (Figure 6), and that 
this increase in -catenin was found to co-precipitate with E-cadherin in the KO livers 
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exclusively (Figure 7), indicating that -catenin was structurally compensating at the AJs for the 
-catenin loss. Additionally, we previously showed that in the KO mice the regulation of -
catenin increase appears to be post-translational, since there was no change in Jup gene 
expression between KO and WT mice, but there was an increase in p-Ser/p-Thr -catenin 
protein (Figure 9). 
5.1.1 β-Catenin knockdown in Hep3B HCC cells 
Initially, we wanted to know if changes in -catenin due to chronic -catenin loss in vivo in 
hepatocytes can also occur acutely in vitro. siRNA-mediated acute knockdown (KD) of -
catenin increased -catenin protein levels in vitro in Hep3B, a human HCC cell line (Figure 
18A) (see section 7.4.1 and Table 2 for siRNA transfection details). As in the in vivo model, 
siRNA KD of -catenin also increased E-cadherin/-catenin co-precipitation in the Hep3B cells 
as compared to the scrambled-siRNA transfected cells (Figure 18B). Reciprocally, -catenin co-
precipitated to a greater extent with E-cadherin upon -catenin KD in Hep3B cells (Figure 18B: 
lower panel). Next we assessed the mechanism responsible for -catenin increase following -
catenin downregulation. We sought any change in mRNA expression of the human -catenin 
gene (JUP) after -catenin KD in Hep3B cells. As in vivo, we did not observe any change in 
JUP expression despite an increase in -catenin protein (Figure 18C). Hence, the in vitro model 
using Hep3Bs accurately replicates key observations seen in hepatocyte-specific KO mice, 
especially at AJ. 
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Figure 18. sKD of -catenin in vitro using multiple HCC cell lines and KD methods accurately replicates 
conditions of in vivo KO, only when protein levels are altered. (A) siRNA (si-catenin) induces efficient 
knockdown of -catenin (92 kDa) in Hep3B cells and leads to an increase of -catenin (83 kDa) protein levels. WB 
for Actin (42 kDa) verifies comparable loading. (B) WCLs from si-catenin and siNegative treated Hep3B cells 
were immunoprecipitated with anti-E-cadherin or anti--catenin antibodies. WB performed for -catenin (upper 
panel) and E-cadherin (120 kDa; lower panel) show differential co-precipitation with si-catenin. (C) Real-time 
PCR for -catenin gene (JUP) and GAPDH reference gene shows insignificant difference in average mRNA 
expression (+/- SD) in si-catenin versus siNegative Hep3B treated cells at 48 hour knockdown (n = 3). (D) HepG2 
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and Hep3B cells treated with ASO to -catenin shows a decrease in -catenin protein and subsequent increase in -
catenin by WB. Both the WT and truncated forms of -catenin in HepG2s show decrease with ASO. WBs for 
GAPDH (37 kDa) and Actin verify comparable loading. (E) Knockdown of -catenin activity using small molecule 
inhibitor ICG-001 does not change the protein levels of - or -catenin, despite the decrease in -catenin 
transcriptional activity as indicated by a decrease in cyclinD1 (37 kDa). 
5.1.2 Other HCC cell lines and alternative knockdowns 
To verify that the observed increase of -catenin in Hep3B cells after siRNA-mediated -catenin 
KD was not cell-specific or reagent-specific, we next employed antisense oligonucleotide (ASO; 
see 7.4.2) to KD -catenin in not only Hep3B but also in HepG2 cells, which carry a monoallelic 
deletion of exon-3 in the CTNNB1 gene. ASO against -catenin decreased its protein levels and 
concomitantly increased the levels of -catenin in both cell lines (Figure 18D). These data 
demonstrate that an increase in -catenin occurs with -catenin decrease regardless of the method 
of protein KD, cell line used, or presence of full-length or mutated -catenin in HCC cells. 
5.1.3 Blockade of β-catenin transactivation does not lead to γ-catenin stabilization 
We next asked if the increase in -catenin occurred secondary to a decrease in -catenin levels, 
its activity, or both. We utilized a small molecule inhibitor of -catenin‟s nuclear functions, ICG-
001 that disrupts the interaction of -catenin and its coactivator CBP, a known histone 
acetyltransferase, to down regulate -catenin/TCF-dependent target genes expression [13] (see 
also 1.3.2; see 7.4.2 for ICG-001 treatment details;). Indeed, treatment of Hep3B cells with ICG-
001 led to decrease in -catenin target cyclinD1 (Figure 18E) and TOPflash luciferase reporter 
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activity (data not shown). However, unlike siRNA or ASO, ICG-001 did not decrease overall -
catenin protein expression (Figure 18E). Intriguingly, ICG-001 treatment did not lead to any 
increase in -catenin in these cells, and if at all a modest decrease was evident in these cells 
(Figure 18E). Thus, this data suggests that cells sense a decrease in total -catenin protein and 
not its activity to trigger an increase in -catenin protein. 
5.2 IN VITRO MODEL OF DOUBLE β- AND γ-CATENIN KNOCKDOWN 
To try and effectively tease out the individual roles of - and -catenin in HCC cells and to 
address biological implications of -catenin stabilization following -catenin KD, we 
investigated the feasibility of double KD (dKD) of - and/or -catenin in addition to single KD 
(sKD) in Hep3B cells via siRNA (see section 7.4.1 and Table 2 for siRNA dKD transfection 
details). Having an in vitro model gives us the ability to modulate the two catenins singly or in 
combination and determine the impact through the simple readouts. Hep3B cells lent themselves 
well for such a model, although the role and regulation of -catenin upon -catenin sKD was also 
evident in other cell lines such as HepG2 cells and by other modalities of KD such as ASOs 
(Figure 20D-E). WB analysis of siRNA-treated Hep3Bs at 24, 48, and 72 hours show that the 
sKD and dKD of these protein is visible by 24 hours post-transfection and persists to at least 72 
hours post-transfection (Figure 19A). Importantly, the increase in -catenin with -catenin sKD 
is apparent at all time points (Figure 19A). Additionally, the Hep3B cells transfected with single 
or double siRNAs appear healthy and viable at all time points tested, and lacked any obvious 
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changes in cell morphology (data not shown). From this data it is evident that in vitro dKD of - 
and -catenin is achievable in Hep3B cells. 
Since -catenin associated with E-cadherin in the absence of -catenin, and -catenin/E-
cadherin association prevents degradation of E-cadherin by masking the PEST domain in E-
cadherin [26], we next asked if -catenin/E-cadherin association could have similar function in 
E-cadherin stability. Hep3B cells subjected to sKD and dKD of catenins were assayed for E-
cadherin levels by WB. While comparable levels of E-cadherin protein were observed in control 
siRNA-transfected Hep3B cells and after sKD of -catenin or -catenin, a notable decrease was 
observed with dKD (Figure 19B). This data suggests that just like -catenin, -catenin can bind 
effectively to E-cadherin and prevent its degradation in HCC cells.  
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Figure 19. dKD of - and -catenin with siRNA in human Hep3B HCC cells persists from 24 through 72 
hours of transfection. (A) Confirmation and time course of sKD and dKD of - and -catenin using siRNA 
technology in Hep3B cells in vitro. KD begins at 24 hours and persists to at least 72 hours after transfection. 
Representative blots shown here (n > 3). WB for GAPDH verifies comparable loading. (B) WB of sKD and dKD 
Hep3Bs show a decrease in E-cadherin expression with dKD of - and -catenin. WB for Actin verifies comparable 
loading. (C) WCL from si-catenin and siNegative treated Hep3B cells were immunoprecipitated with an anti--
catenin antibody. WB shows no changes in -catenin‟s association with AJ protein E-cadherin. WB for -catenin 
indicates pull-down efficiency. 
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5.2.1 β-Catenin increase with γ-catenin loss in HCC cells 
Interestingly, -catenin KD in Hep3B cells lead to an increase in -catenin protein expression, 
especially at 24 and 48 hours of -catenin siRNA transfection (Figure 19A). This is in agreement 
with the recent cardiomyocyte-specific -catenin knockout mice, which show an increase in -
catenin protein levels; however, the literature is mixed on the role of this -catenin pool [188, 
189]. One study shows that the increase in -catenin with -catenin loss is localized to the AJ 
[188], while another report suggests this increase to be nuclear since it led to an increase in -
catenin target gene expression [189]. Therefore, we looked at the AJ composition with -catenin 
sKD to see if there are any changes in -catenin/E-cadherin association. We observe no apparent 
changes in their association in -catenin sKD (Figure 19C), indicating that the increase in -
catenin is most likely occurring in the cytoplasmic/nuclear and potentially the signaling pool of 
-catenin in HCC cells. 
5.3 γ-CATENIN DOES NOT COMPENSATE FOR β-CATENIN-MEDIATED WNT 
SIGNALING 
We have reported previously a lack of nuclear -catenin in hepatocyte-specific -catenin KO 
mice even at time of -catenin-dependent hepatocyte proliferation, such as 72 hours after partial-
hepatectomy (Figure 8), indicating that -catenin was not compensating for nuclear -catenin 
signaling in vivo [91]. To test this in vitro, we used a TOPflash luciferase reporter to assess TCF-
dependent signaling of - and -catenin (see Figure 23 for vector map and 7.4.4 for transfection 
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details). As expected, sKD of -catenin led to decreased TOPflash activity (Figure 20A) (see 
7.11.1 for luciferase assay details). A dKD of - and -catenin showed a decrease in Wnt 
signaling, but there was no additional impact of -catenin KD on the TOPflash reporter activity 
(Figure 20A), suggesting that -catenin does not contribute to Wnt signaling and therefore 
cannot compensate for -catenin loss in this capacity in HCC cells.  
Interestingly, there was a significant increase in TOPflash activity with -catenin sKD at 
48 hours post-transfection (Figure 20A). This was in agreement with the increase in -catenin 
levels in the non-E-cadherin bound fraction after -catenin sKD (Figure 19A), and further 
supports the hypothesis that the increased -catenin after -catenin sKD participates in Wnt 
signaling [189]. To directly address this biologically, we examined [3H]thymidine-incorporation 
with dKD and sKD of - and -catenin as a measure of cell proliferation (a -catenin-dependent 
event). As expected, and in agreement with TOPflash reporter activity, we observed a decrease 
in [3H]thymidine incorporation after sKD of -catenin or dKD of both catenins. However, also 
in concordance with TOPflash results, there was an increase in proliferation with -catenin sKD, 
albeit at 72 hours and not 48 hours after KD (Figure 20B), which is most likely due to 
physiological delay in transactivation of cell cycle related target genes governing this event. 
From this data it is evident -catenin does not compensate for -catenin-mediated Wnt signaling 
in vitro, but -catenin knockdown is able to increase -catenin-TCF reporter activity in HCC 
cells. 
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Figure 20. -Catenin does not compensate for -catenin-mediated Wnt signaling in vitro. (A) Wnt reporter 
(TOPflash) activity for sKD and dKD shows a significant decrease in activity with sKD of -catenin and dKD, but a 
significant increase with sKD of -catenin at 48 hour KD (p<0.01; +/- SD). (B) (Upper panel) Thymidine-
incorporation values for sKD and dKD shows a significant decrease in activity with sKD of -catenin and dKD, but 
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no difference with sKD of -catenin at 48 hour KD. (Lower panel) [3H]Thymidine-incorporation values for sKD 
and dKD at 72 hours shows a significant decrease in activity with sKD of -catenin and dKD, but a significant 
increase with sKD of -catenin at 48 hour KD (p<0.01; +/- SD; *indicates significance as compared to siNegative; 
N.S. = not significant). 
5.4 ONLY DOUBLE KNOCKDOWN OF β- AND γ-CATENIN NEGATIVELY 
AFFECTS CELL-CELL ADHESIONS 
5.4.1 HCC cell migration 
We next queried if -catenin upregulation after -catenin KD in HCC cells would conserve cell 
adhesions comparable to -catenin. Hep3B cells after sKD or dKD were used for scratch-wound 
assay to measure cell migration as described in 7.12.1. We observe that while a sKD of either -
catenin or -catenin alone led to no significant change is the percentage of wound closure after 
24 hours, dKD of both catenins significantly enhanced wound closure at this time when 
compared to Hep3Bs treated with a negative control siRNA (Figure 21A-B). This data indicates 
that the dKD of - and -catenin is detrimental to overall cell adhesion thus increasing cell 
migration, while sKD of -catenin is adequately compensated by -catenin. Additionally, sKD of 
-catenin has no impact on AJs since E-cadherin/-catenin association remains unaltered as 
shown earlier (Figure 18B). 
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Figure 21. dKD of - and -catenin affects cell migration and cell-cell adhesion in HCC cells. (A) 
Representative images of wound closure at 24 hours after initiation of the wound and 48 hours after transfection 
with various siRNAs. (B) Scratch-wound assay for sKD and dKD Hep3B cells shows a significant increase in 
wound closure percentage for dKD of - and -catenin only (*p < 0.01; +/- SD). (C) Centrifugal Assay for Cell 
Adhesion (CAFCA) with sKD and dKD Hep3B cells shows a significant decrease heterotypic cell-cell adhesion 
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with dKD of - and -catenin only as measured by increase in percentage of cells which de-adhere from the 
monolayer after centrifugation at 375g for 10 minutes (*p < 0.01; +/- SD; *indicates significance as compared to 
siNegative). (D) Hanging-drop assay shows that at 24 hour after drop formation (72 hour transfection) the colonies 
formed appear similar in size, though the dKD colonies appear to be less symmetric than the sKD and siNegative 
colonies (upper panel). After pipetting, the dKD cells dissociate the most, indicating weaker homotypic cell-cell 
adhesions (lower panel). Addition of EGTA, a calcium-chelator, was used as a control to show that colonies formed 
were calcium-dependent or cadherin-based cell-cell adhesion (inset). 
5.4.2 Heterotypic cell-cell adhesions 
To more directly test the functionality of -catenin at cell-cell adhesions after -catenin KD, we 
next employed a centrifugal assay for cell adhesion (CAFCA) to compare the overall strength of 
cell-cell adhesions after sKD and dKD using Hep3B cells as described in 7.12.2. siRNA-treated 
Hep3B cells were plated on an untreated monolayer of Hep3Bs and subjected to a centrifugal 
force of 375g. At this force we observed a significant decrease in cell-cell adhesion as measured 
by an increase in the percentage of cells lost, only with the dKD of - and -catenin, when 
compared to control or sKD (Figure 21C). Therefore, dKD, but not sKD of - and -catenin, 
negatively impacts cell-cell adhesions. 
5.4.3 Homotypic cell-cell adhesions 
To further validate cadherin-mediated cell-cell adhesions specifically (as in [113]) we used a 
hanging-drop assay, where transfected cells were cultured in suspension (see 7.12.3 for details). 
After 24 hours in suspension, all the treatments formed colonies of relatively similar size; 
however, the dKD colonies appeared smaller and more asymmetric than others (Figure 21D, 
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upper panel). To confirm that we were measuring calcium-dependent or cadherin-mediated 
adhesion, the single-cell suspension of Hep3B cells was also cultured in the presence of EGTA, a 
calcium-chelator. This led to the absence of any colony formation after 24 hours, indicating that 
indeed these colonies required calcium to make new cell-cell adhesions (Figure 21D; inset). 
When the colonies of hanging-drop cultures were triturated, only the dKD conditions dissociated 
readily to a single cell suspension, indicating weaker homotypic intercellular adhesions (Figure 
21D, lower panel). From this data it is evident that dKD of - and -catenin in Hep3B cells 
negatively affects cell-cell adhesion. Taken together with 5.4.2, the data supports maintenance of 
AJ by -catenin upon -catenin loss and that concomitant decrease of - and -catenin will be 
detrimental to intercellular adhesion and effectiveness of AJ. 
5.5 DISCUSSION: BIOLOGICAL IMPLICATIONS IN HCC 
The first part of our study demonstrated that decreasing -catenin levels blocks canonical Wnt 
signaling, which is the major contributor towards HCC cell proliferation and survival. While -
catenin sKD increases -catenin, this increase is unable to compensate for -catenin signaling as 
a part of the canonical signaling pathway as shown by TOPflash reporter activity. Similarly, 
despite -catenin increase in KO livers, several liver-specific targets of -catenin such as GS, 
cytochrome P450s CYP2E1 and CYP1A2 continued to be significantly downregulated, again 
affirming no role of -catenin in compensating as a component of Wnt signaling in a normal liver 
[34]. 
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Next we showed that adhesion of Hep3B cells to an untreated monolayer of Hep3B cells 
via CAFCA was decreased upon dKD of - and -catenin. This result was not profound, but 
significant. We can ascribe the modest changes in the CAFCA results to junctional cross-talk and 
compensation, which we have previously observed in the in vivo KO of -catenin [41, 91], and 
have also been seen in the in vivo models of -catenin knockdown/knockout as well [189, 190]. 
There are known nodes of cross-talk between AJ and desmosomes [70], AJ and tight junctions 
[69], along with AJ and gap junctions [71] (see section 1.5). We propose that these important 
redundancies built into the overall physiology of epithelial cells help enable maintenance of cell-
cell adhesions with any therapeutic treatment that would affect a junctional protein such as -
catenin.  
In order to tease out the exact roles of - and -catenin on desmosomes and AJ, we used 
more specific assays for isolating cadherin-mediated adhesions. The hanging-drop assay 
confirmed that cadherin-mediated adhesion is greatly decreased with the dKD of - and -
catenins, but not with either sKD. This indicates that at least one of these catenins is necessary 
for the proper maintenance of cadherin-mediated junctions, corroborating the data put forth by 
previously [113]. This data may also be influenced by the fact that we see an overall decrease in 
E-cadherin levels in our dKD Hep3Bs, which would reduce the pool of E-cadherin available for 
dimerization and assembly of AJ and would most likely reduce the overall number of AJ as well 
(Figure 21B). The decrease in E-cadherin levels may be a result of the lack of catenins available 
to traffic E-cadherin to the membrane. -Catenin is known to interact with E-cadherin in a way 
that masks the PEST domain of E-cadherin, which is necessary for E-cadherin‟s recognition by 
the proteasome [166]. Thus, based on the similarities of - and -catenin‟s interactions with E-
cadherin [111], we assume that -catenin may also play a role in E-cadherin stabilization by 
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masking its PEST domain, at least in vitro, and after acute -catenin KD. Indeed, various studies 
have shown that the interactions of -catenin and -catenin with similar regions on E-cadherin 
are indistinguishable [111]. Thus, at least one of the two catenins is necessary for the 
maintenance of cadherin-mediated junctions and for steady state expression of E-cadherin. 
The data presented in this chapter supports the conclusion that -catenin increase 
secondary to -catenin sKD does not worsen HCC cell phenotype by promoting tumor cell 
proliferation, migration or Wnt activation. Others have published studies indicating that an 
increase in -catenin leads to enhancement of metastasis through genomic instability and 
migration [135]. However, we accredit the lack of detrimental phenotypes seen with -catenin 
increase with sKD of -catenin to a strictly compensatory function of -catenin in lieu of -
catenin at the AJ. Thus, -catenin appears to have a protective effect when -catenin levels are 
decreased. However, on its own -catenin appears to have rather mixed effects. While on one 
hand sKD of -catenin did not negatively impact cell-cell adhesions or migration, we did observe 
an increase in proliferation preceded by an increase in -catenin signaling. Therefore, in our 
studies we observed that -catenin does not explicitly act as an oncogene or tumor suppressor, 
but that its role in HCC cells may be closely linked to that of -catenin or the intact AJs, 
although additional studies like hepatocyte-specific conditional KO of -catenin would be 
necessary. This was also shown previously in a HCC patient samples, where it was not the 
overall levels of catenins that determined the prognosis of HCC, but instead progression 
correlated better with AJ expression as measured by combined expression of catenins and E-
cadherin [158]. Specifically, the authors observed poor prognosis and survival rate in HCC 
patients exhibiting decrease in both -catenin and E-cadherin and not a decrease in -catenin 
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alone [158]. Our data thus suggests that only combined inhibition of -catenin and -catenin 
leads to more migration of cells and perhaps may induce local invasion and metastasis. We 
assume that the AJs are also greatly affected in this cases as indicated by decrease in cell-cell 
adhesions. Therefore, anti--catenin therapies for HCC appear to be feasible, as long as -catenin 
is spared. 
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6.0   γ-CATENIN AT ADHERENS JUNCTIONS AFTER β-CATENIN LOSS: 
MECHANISMS IN HEPATOCELLULAR CARCINOMA 
We have previously demonstrated in KO mice that the increase in -catenin protein levels is not 
regulated at the mRNA level, and that -catenin stabilization is most likely a result of increased 
serine/threonine phosphorylation of cytoplasmic -catenin (Chapter 2). Here further elucidate 
the mechanism of -catenin stabilization via serine/threonine phosphorylation, identifying 
protein kinases A (PKA) and PKG as the most likely candidates for these phosphorylation 
events. This allows for -catenin-lowering agents as a viable option for treatment of HCC, 
provided -catenin stabilization mechanisms are spared. 
6.1 NO CHANGE IN JUP TRANSCRIPTION WITH β-CATENIN KNOCKDOWN 
We showed in Chapter 5 that there is no change in human JUP mRNA levels in an in vitro 
model of acute -catenin loss in HCC cells, and that the stabilization of -catenin in the context 
of -catenin loss must be regulated at a post-transcriptional level, as in the in vivo mouse model 
of chronic -catenin loss (KO). 
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6.2 SERINE/THREONINE PHOSPHORYLATION STABILIZES γ-CATENIN 
AFTER β-CATENIN KNOCKDOWN 
Based on in vivo observations that -catenin increase with -catenin loss in KO livers was 
associated with increased serine and threonine phosphorylation of -catenin, we asked whether 
such posttranslational modification could in fact stabilize -catenin in vitro. As described in 
section 7.4.3, we treated Hep3B cells with Okadaic acid (OA), a well-known inhibitor of 
serine/threonine phosphatases [191, 192]. Treatment of Hep3B cells for 3 hours with OA led to 
an increase in total -catenin protein levels further supporting the role of serine/threonine 
phosphorylation in its stabilization (Figure 22A). 
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Figure 22. Mechanism of -catenin stabilization after sKD of -catenin. (A) Treatment of Hep3B cells for 3 
hours with 10 or 25 nM Okadaic acid (OA), a known serine/threonine phosphatase inhibitor, results in increase in -
catenin (83 kDa) as shown in a representative WB. WB for GAPDH (37 kDa) verifies comparable loading.  (B) 
Treatment of Hep3B cells with various serine/threonine kinase inhibitors for 3 hours after 45 hours of transfection 
with control or -catenin siRNA reveals a decrease in stabilization of -catenin after PKG inhibitor (PKGI) and H-
89 (PKA inhibitor) only in representative WBs. (C) As shown in a representative WB, treatment of Hep3B cells 
with H-89 at 150 nM and 20 M for 3 hours after 21 or 45 hours of transfection with si-catenin or siNegative 
reveals a dose-and time-dependent decrease in extent of -catenin stabilization. 
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6.3 PKA/PKG REGULATE γ-CATENIN PHOSPHORYLATION AND 
STABILIZATION 
To address which specific serine/threonine kinases may be responsible for -catenin stabilization 
in Hep3B cells after -catenin sKD, we utilized six different inhibitors with a broad range of 
activity. As described in section 7.4.3, at around 45 hours after transfection of Hep3B cells with 
-catenin or control siRNA, the cells were treated with the inhibitors: H-89 (inhibits PKA, CaM 
Kinase II, PKC and Casein Kinase I); PKG Inhibitor (PKGI; inhibits PKG and PKA); 
Bisindolylmaleimide I (PKC inhibitor); KN-93 (CaM Kinase II inhibitor only); ML-7 (inhibits 
Myosin Light Chain Kinase) and Staurosporine (broad range). We compared the extent of 
increase of -catenin upon -catenin sKD following treatment with these inhibitors. A notable 
decrease in -catenin was evident only after Hep3B cells were treated with PKG or PKA 
inhibitor, while -catenin levels continued to increase in the presence of all other inhibitors 
(Figure 22B). The impact of PKA inhibition was more robust than PKG and since the PKGI was 
utilized at higher dose (200 M) that also inhibits PKA. Therefore, we concluded an important 
role of PKA in -catenin stabilization.  
We further studied response to 3 hours of H-89 at low (150 nM) and high (20 M) 
concentration on -catenin expression at 21 and 45 hours after -catenin or control siRNA 
transfection sKD. Both doses are within the range of specifically inhibiting PKA since 
concentration of only 30 M or more impacts other serine/threonine kinases such as CaM Kinase 
II, Myosin Light Chain Kinase and Casein Kinase I [193]. While a modest decrease in extent of 
-catenin increase upon siRNA-mediated -catenin was observed in Hep3B cells at 20 hours at 
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both doses of H-89, maximal inhibition was evident at 48 hours and at 20 M H-89 
concentration thus reinforcing the role of PKA in -catenin stabilization process (Figure 22C). 
6.4 DISCUSSION: MECHANISMS IN HCC 
This part of our study addressed the molecular basis of -catenin increase following -catenin 
loss. In our previous work, -catenin increase in -catenin KO mice was not due to 
transcriptional regulation, but we identified enhanced serine/threonine and not tyrosine 
phosphorylation of -catenin [91]. This mechanism was also verified in vitro when OA, a known 
serine/threonine phosphatase inhibitor induced -catenin levels in Hep3B cells [191, 192, 194, 
195]. -Catenin is indeed known to undergo serine/threonine phosphorylation [115]. Since 
cytoplasmic but not insoluble-membrane associated pool of -catenin showed serine and 
threonine phosphorylation, it suggests that phosphorylation may prevent -catenin degradation 
during cytoplasmic trafficking (Figure 9B), although this will need to be further investigated. In 
our studies, based on the overlap of activities of various kinase inhibitors used and observed 
dose-dependent response, it appears that PKA is the candidate serine/threonine kinase 
responsible for phosphorylating -catenin to induce its stabilization in the absence of -catenin. 
Additional studies to identify the specific effector residues on -catenin are ongoing. 
Preclinical -catenin inhibitors being investigated can be broadly categorized into two 
classes: 1) that block the nuclear -catenin without impacting the total levels of -catenin (such 
as ICG-001 and Pegylated Interferon-2a) [12, 13], and 2) the inhibitors that suppress -catenin 
gene and/or protein expression such as ASO or other indirectly acting agents [11, 59, 196-198]. 
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Results from ASO, siRNA and ICG-001 studies indicate that it is the absolute levels of -catenin 
and not a decrease in -catenin‟s transactivational activity (Figure 18D-E), which provides an 
impetus for -catenin stabilization. Additionally, the compensation by -catenin is at the AJ only 
and the functions of -catenin as a part of the Wnt pathway remain unfulfilled by -catenin 
(Figure 20A). This suggests that there may be a catenin-sensing mechanism in a cell, which 
monitors the levels of catenins especially at junctions and allows for compensation for these 
proteins by others via relatively prompt posttranslational modifications. We propose that PKA 
may be such as sensor, which stabilizes -catenin and is also known to phosphorylate -catenin 
at Ser552 and Ser675 to induce its activation [20]. Whether PKA normally phosphorylates 
membrane bound -catenin is not known, although the two effector serine/threonine sites are in 
close proximity to Tyr654 and Tyr670, which are the sites phosphorylated by receptor tyrosine 
kinases known to deregulate E-cadherin/-catenin complex at AJ [23, 199]. We therefore 
propose that when -catenin levels diminish, PKA is unable to activate -catenin, which now 
switches substrates to phosphorylate -catenin instead and this induces -catenin stabilization to 
at least fulfill the role of -catenin at the AJ. While this hypothesis needs further experimental 
proof, it does demonstrates the feasibility of -catenin-decreasing agents as therapies for HCC, 
provided -catenin stabilization factors such as PKA are spared for adequate compensation at 
junctions to prevent untoward effects on tumor cell migration, invasion and metastasis. 
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7.0  MATERIALS AND METHODS 
7.1 ANIMALS 
7.1.1 βKO mice 
Homozygous floxed -catenin mice (Ctnnb1lox/lox; C57BL/6 strain) and Albumin-Cre (Alb-Cre; 
C57BL/6 strain) transgenic mice from Jackson Laboratories (Bar Harbor, ME) were strategically 
bred as previously described [34]. Briefly, mice with homozygous floxed -catenin gene were 
bred to Albumin-Cre mice. The offspring with both 1) a floxed -catenin allele (and wild-type 
allele) and 2) Albumin-Cre allele were then bred to homozygous floxed -catenin mice to delete 
the floxed regions of the -catenin gene (exons 1-6). Mice with genotypes Ctnnb1lox/lox;Alb-
Cre
+/-
 are referred to as knockouts (KO). Age- and sex-matched littermates with other 
genotypes were used as wild-type controls (WT): Ctnnb1
loxp/loxp
;Alb-Cre
-/-
 or Ctnnb1
loxp/wt
;Alb-
Cre
+/-
 or Ctnnb1
loxp/wt
;Alb-Cre
-/-
. Livers from age- and sex-matched 60–120 day-old KO and 
WT mice were used, unless otherwise noted. At least n < 3 KO and WT animals were used for 
each analysis to account for animal-to-animal variations. Animals were harvested by CO2 
asphyxiation. All animal studies were approved by University of Pittsburgh IACUC office. 
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7.1.2 Sample preparation 
Mice under isoflurane inhalation anesthesia were killed by cervical dislocation. Animals were 
harvested by CO2 asphyxiation. The livers were extracted, washed in PBS, and then the tissue 
was processed in three ways: 1) embedded in paraffin blocks (after 10% formalin fixation), 2) 
stored in Tissue-Tek OCT (Sakura Finetek, Dublin OH) at -80
o
C, and/or 3) flash frozen in liquid 
nitrogen and stored at -80
o
C until use.  All animal studies were approved by University of 
Pittsburgh IACUC office. 
7.2 SURGERIES AND DIETS 
7.2.1 Partial hepatectomy 
Surgical removal of 2/3 of the mouse liver was used to induce liver regeneration. Surgeries were 
performed as previously described [200]. Briefly, three of the five lobes were individually tied 
and then surgically resected before suturing up the animal. The regenerating livers were harvest 
at 40 and 72 hours. 
7.2.2 DDC diet 
Mice were fed a special chow containing 0.1% 3,5-diethoxycarbonyl-1,4-dihydrocollidine 
(DDC) (Bioserve, Frenchtown, NJ) for 3 to 150 days to induce atypical ductular proliferation as 
previously described [201]. 
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7.3 CELL LINES 
Hep3B and HepG2 human HCC cell lines were obtained from the American Type Culture 
Collection (Manassas, VA). Hep3B cells express a wild-type -catenin species, while the 
HepG2s have an exon-3 deleted/constitutively active form of -catenin [202]. Cells were 
cultured in Eagle‟s minimal essential medium (EMEM) supplemented with 10% vol/vol fetal 
bovine serum (FBS) at 37
o
C in a humidified 5% carbon dioxide atmosphere, unless otherwise 
noted. Cells were passaged using 0.25% Trypsin-EDTA. 
7.4 IN VITRO TREATMENTS 
7.4.1 Small interfering RNAs 
Human -catenin (JUP), pre-validated -catenin (CTNNB1), and scrambled Negative Control 2 
Silencer Select small interfering RNAs (siRNA) were purchased from Ambion (Grand Island, 
NY). For transient transfections using siRNA, the cells were initially plated in 6-well plates and 
grown to 60% - 80% confluence, followed by serum starvation 4-16 hours in EMEM without 
FBS. The cells were transfected using Lipofectamine-2000 (Life Technologies, Grand Island, 
NY) and a total siRNA concentration of 25 to 75 nM (Table 2) in OPTI-MEM I Media (Life 
Technologies, Grand Island, NY) for 24 to 72 hours as per the manufacturer‟s instructions. 
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Table 2. siRNA concentrations for single and double knockdown of - and/or -catenin. 
 
7.4.2 β-Catenin/Wnt inhibitors 
Small molecule inhibitor of -catenin‟s nuclear activity, ICG-001 (MW = 548 g/mol, IC50 = 3 
M) [13], was used for cell treatments at 10 M. ICG-001 selectively disrupts the interaction of 
-catenin with its nuclear coactivator CBP which disrupts TCF-driven gene transcription [13]. 
Additionally, CTNNB1 (ISIS102708) or control antisense oligonucleotides (ASO; ISIS 
Pharmaceuticals Inc., Carlsbad, CA) were used at a concentration of 50 nM as previously 
published [42]. For transient transfection using ASOs, the cells were transfected in a similar way 
to the siRNAs (7.4.1) using Lipofectamine-2000 (Life Technologies, Grand Island, NY) in 
OPTI-MEM I Media (Life Technologies, Grand Island, NY) for 24 to 72 hours as per the 
manufacturer‟s instructions.  
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7.4.3 Phosphatase/kinase inhibitors 
Cells were treated with the phosphatase inhibitor Okadaic Acid (OA) (Santa Cruz 
Biotechnology, Santa Cruz, CA) at 25 nM and 10 nM as previously published for HCC cells 
[195] for 3 hours, along with DMSO controls ([DMSO]f < 2%). Serine/Threonine kinase 
inhibitors, purchased from  Calbiochem (Billerica, MA), were administered for 3 hours, with 
relevant DMSO controls, at the following concentrations: H-89 at 150 nM and 20 M [203]; 
PKG Inhibitor (RKRARKE) at 200 M [194, 204]; Bisindolylmaleimide I at 1 M [205]; KN-93 
at 5 M [206]; ML-7 at 30 M [207]; and Staurosporine at 1 M [208]. Kinase targets and 
selectivity for these inhibitors can be found in Table 3 (adapted from Adapted from Calbiochem 
“Serine/Threonine Kinase Inhibitor Set” data sheet – Product 539572). 
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Table 3. Phosphatase inhibitors and serine/threonine kinase inhibitors used in vitro. 
 
7.4.4 TOPflash reporter plasmid 
The reporter construct TOPflash (Upstate, Lake Placid, New York) has three copies of TCF/LEF 
-catenin binding sites upstream of a thymidine kinase (TK) promoter and the firefly luciferase 
(Figure 23). For transient transfections using TOPflash, the cells were transfected in a similar 
way to the siRNAs (7.4.1) using Lipofectamine-2000 (Life Technologies, Grand Island, NY) in 
OPTI-MEM I Media (Life Technologies, Grand Island, NY) at a total concentration of 400 ng 
for 24 to 48 hours as per the manufacturer‟s instructions. Cells were also co-transfected with 100 
ng Renilla Luciferase plasmid to control for transfection efficiency.  
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Figure 23. Schematic of TOPflash vector used for Wnt Signaling studies. 
7.5 RNA EXTRACTION 
RNA was extracted from tissue or cells using TRIZOL (Life Technologies, Grand Island, NY) as 
per the manufacturer‟s instructions. Briefly, 1 mL TRIZOL reagent was used per 
sample/extraction. RNase-free chloroform was added at a volume equal to 20% of the TRIZOL 
volume and shaken vigorously. Samples were centrifuged at 12000 rpm and 4
o
C to facilitate a 
phase separation of the RNA. The top, colorless, aqueous, RNA-containing phase was used to 
continue the extraction. RNase-free isopropyl alcohol was added at 150% the volume of 
chloroform and incubated at 4
o
C to precipitate the RNA. The samples were centrifuged at 12000 
rpm and 4
o
C, and the RNA pellet was washed with 75% EtOH (RNase-free) before resuspension 
in DPEC-treated or RNase-free water. 
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7.6 mRNA EXPRESSION STUDIES 
7.6.1 Sample preparation 
RNA was extracted as in 7.5 and subsequently DNAse-treated to remove potential genomic 
DNA contamination using the TURBO DNAse Kit (Ambion, Grand Island, NY) as per the 
manufacturer‟s instructions. 
7.6.2 Real-time PCR 
DNase-treated RNA was used for real-time PCR analysis with the SYBR-Green Master Mix 
(Ambion, Grand Island, NY) as described elsewhere [41]. Briefly, the OD of the DNase-treated 
RNA was taken and equal g amounts of RNA from each sample were used to make individual 
cDNA samples using SuperScript III First–Strand Synthesis System for RT-PCR with an RNase 
H treatment (Life Technologies, Grand Island, NY). A total of 0.1 g cDNA along with 1x 
Power SYBR-Green PCR Master Mix (Applied Biosystems, Grand Island, NY) and the 
appropriate primers were used for each real-time PCR reaction (see Table 4; references: Zhu et 
al., 2008 [209]; Jackson Laboratories [210]; Primer-BLAST [211]; Cicinnati et al., 2008[212]). 
The Applied Biosystems StepOnePlus Real-Time PCR System was used for the analysis of the 
transcripts with the StepOne v2.1 software. Comparative CT was used for analysis of the data, 
and calculations were made without the StepOne software (Applied Biosystems, Grand Island, 
NY). Primer efficiencies were performed for each primer, and only similar efficiencies were 
used for analysis. Comparative CT from triplicate animals/experiments were compared for 
statistical significance by Student‟s t-test. 
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Table 4. Real-time PCR primers. 
 
7.6.3 Microarray 
Livers from three KO and WT mice were used for Affymetrix (Santa Clara, CA) gene array 
analysis as previously published [34]. The signals from KO and WT livers were compared and 
presented as fold-change. 
7.7 PROTEIN EXTRACTION 
7.7.1 Whole-cell lysates 
Whole-cell lysates were obtained using RIPA buffer (1% Igepal CA-630, 0.5% Sodium 
Deoxycholate, 0.1% SDS in PBS) containing fresh protease and phosphatase inhibitor cocktail 
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(Sigma Aldrich, St. Louis, MO) as described previously [34]. BCA protein assays (Pierce, 
Rockford, IL) were performed to ensure equal protein concentrations for all subsequent 
experiments. 
7.7.2 Cytoskeletal-associated lysates 
Cytoskeletal-associated proteins were extracted from both WT and KO livers as previously 
described by Hinck et al. [166], with additional modifications from Hugh et al. [213], and also 
by our lab [91]. The samples were homogenized in 200 l Lysis Buffer A (1% Triton X-100, 50 
mM Tris-HCl pH 7.5, 1 mM EGTA, 5 mM EDTA, 140 mM NaCl, 10% glycerol, 1 mM MgCl2) 
and fresh protease and phosphatase inhibitor cocktail (Sigma Aldrich, St. Louis, MO) and 
incubated on ice for fifteen minutes. The samples were homogenized once more and incubated 
for another fifteen minutes on ice. Next, the samples were centrifuged for twenty minutes at 
3000 rpm at 4°C. The supernatant (Triton-soluble or unbound cytosolic fraction; “S”-fraction) 
was separated from the pellet. The residual pellet was extracted in 200 l Lysis Buffer B (1% 
SDS, 50mM Tris-HCl pH 7.5, 1 mM EGTA, 5 mM EDTA) and fresh protease and phosphatase 
inhibitor cocktail (Sigma Aldrich, St. Louis, MO) by homogenizing pellet and then incubating 
samples at 100
o
C for ten minutes. The samples were diluted in 500 l Lysis Buffer A and 
centrifuged for twenty minutes at 3000 rpm at 4°C. This last supernatant represents the Triton-
insoluble or cytoskeletal-associated fraction (“I”-fraction). BCA protein assays (Pierce, 
Rockford, IL) were performed to ensure equal protein concentrations for all subsequent 
experiments. 
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7.7.3 Nuclear lysates 
Nuclear extracts were performed from fresh liver tissue using the NE-PER Nuclear and 
Cytoplasmic Extraction Reagents (Thermo Fisher Scientific, Waltham, MA) as per the 
manufacturer‟s instructions. Briefly, 50 – 100 mg of tissue was homogenized in CER I reagent, 
vortexed, and incubated on ice for ten minutes before ice cold CERII, at a volume equal to 5.5% 
of the  CER I reagent, was added to the samples, vortexed, and centrifuged for five minutes at 
13000 rpm. The supernatant was saved as a “cytoplasmic extract,” and the residual pellet was 
extracted with the NER reagent by incubating on ice for forty minutes and vortexing 
occasionally. The NER was spun down at 13000 rpm for ten minutes, and the supernatant was 
used as the “nuclear extract.” BCA protein assays (Pierce, Rockford, IL) were performed to 
ensure equal protein concentrations for all subsequent experiments. 
7.8 PROTEIN EXPRESSION STUDIES 
7.8.1 Western blot 
A total of 10–50 g of protein were resolved on Tris–HCl precast gels (Bio-Rad Laboratories, 
Hercules, CA) by SDS-PAGE analysis using the mini-PROTEIN 3-electrophoresis module 
assembly (Bio-Rad Laboratories, Hercules, CA). The resolved proteins were transferred to 
polyvinylidene difluoride (PVDF) membranes and signal detected by Super-Signal West Pico 
Chemiluminescent Substrate (Pierce, Rockford, IL). Horseradish-peroxidase-conjugated 
secondary antibodies were purchased from Millipore (Billerica, MA). See Appendix A for 
 107 
complete list of antibodies and dilutions used for western blots (WB). Image J software (National 
Institutes of Health, Bethesda, MD) was used for densitometry analysis of relative protein levels 
and levels were normalized to GAPDH or -actin reference proteins. Arbitrary units from 
triplicate animals/experiments were compared for statistical significance by Student‟s t-test. 
7.8.2 Immunoprecipitation 
Immunoprecipitation (IP) studies were performed with 500 g of cell lysates. All sample lysates 
were pre-cleared by adding 0.25 g control IgG (same as primary antibody species) and A/G-
agarose beads (Santa Cruz Biotechnology, Santa Cruz, CA). A total of 0.2–2.0 g of primary 
antibody was added to pre-cleared cell lysates for 1 hour followed by addition of 20 l of A/G 
agarose beads. Alternatively, 10 l -catenin-pre-conjugated A/G agarose beads (sc-1496 AC; 
Santa Cruz Biotechnology, Santa Cruz, CA) were added to the lysate after pre-clearing. Samples 
were rotated at 4
o
C overnight. The proteins were eluted from the beads by adding 2x laemmli 
buffer and boiling samples. Equal volumes were run on SDS-PAGE gels and immunoblotted as 
described in 7.8.1. The comparable input between various groups was verified by WBs against 
the protein used for pull downs. See Appendix A for complete list of antibodies and dilutions 
used for IPs.  
7.8.3 Immunohistochemistry 
Immunohistochemical stains were performed as previously described [34]. Briefly, tissue 
samples were embedded in paraffin and cut into 4 sections. The slides were deparaffinized with 
xylene and graded alcohol washes and rinsed in PBS. The tissue sections were microwaved twice 
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in citrate buffer for twelve minutes total, and then endogenous peroxidases were quenched with 
3% hydrogen peroxide. Slides were blocked with Super Block (UltraTek, West Logan, UT) for 
ten minutes before adding primary antibody diluted in PBS for 1 hour at room temperature. After 
PBS washes, horseradish-peroxidase-conjugated secondary antibodies (Millipore, Billerica, MA) 
were added to the slides for 1 hour at room temperature. The secondary antibody signal was 
detected with DAB (Vector Labs, Southfield, MI), and the signal was quenched with dH2O 
before counterstaining with Harris hematoxylin solution (Sigma Aldrich, St. Louis, MO). The 
slides were re-run through the xylene and graded alcohol washes before mounting the cover slips 
with DPX (Fluka Labs, St. Louis, MO). Negative controls were generated as above, but without 
the primary antibody incubation. IHC images were taken on an Axioskop 40 (Zeiss, Thornwood, 
NY) inverted brightfield microscope. See Appendix A for complete list of antibodies and 
dilutions used for immunohistochemistry (IHC). 
7.8.4 Immunofluorescence 
Analysis was performed on OCT embedded tissue which was sectioned at 4 – 6 on a cryostat 
set at -20
o
C. The samples were fixed by various methods (See Appendix A for antibody-specific 
fixation methods). The OCT was removes from the tissue sections with three PBS at room 
temperature. The tissue was then permeablized by various methods (See Appendix A for 
antibody-specific permeablization  methods) for ten minutes at room temperature, and washed 
again three times with PBS. The tissue was then blocked with 2% BSA/PBS for forty-five 
minutes, and washed five times with PBB (PBS + 0.5% BSA). Primary antibodies diluted in 
PBB were applied either for 1 hour at room temperature, or overnight at 4
o
C. After the primary 
antibody, the sections were washed five times in PBB. The secondary antibody was applied in a 
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covered chamber for forty minutes at room temperature. For these studies, the following 
secondary antibodies were used: donkey anti-goat Alexa-488; donkey anti-rabbit Alexa-555; and 
Cy5 Phalloidin counterstain for actin (Life Technologies, Grand Island, NY). After the 
secondary antibody incubation, the sections were washed five times with PBB and five times 
with PBS before applying Hoechst 33258 (Sigma Aldrich, St. Louis, MO)  for two minutes at 
room temperature. The sections were washed three more times with PBS and coverslips were 
mounted with gelvatol (21 g PVA, 42 mL glycerol, 52 mL dH20, 106 mL Tris [0.2M, pH=8.5], 
and a few crystals of sodium azide). Negative controls were generated as above, but without the 
primary antibody incubation. All images were taken on the Olympus Fluoview 500 or 1000 at 
the University of Pittsburgh Center for Biological Imaging (CBI). All images shown were taken 
using a UPLAPO 20x O (NA = 0.80) on the Olympus 500 and a PLAPON 20x O (NA = 0.80) on 
the Olympus 1000. See Appendix A for complete list of antibodies and dilutions used for 
immunofluorescence (IF). 
7.9 ULTRASTRUCTURE STUDIES 
7.9.1 Transmission electron microscopy 
Liver tissue was fixed with 2.5% glutaraldehyde in PBS by perfusion via the inferior vena cava. 
The tissue was then cut into 1 mm
3
 blocks and washed three times for fifteen minutes in PBS at 
room temperature. The tissue sample was post fixed in 1% osmium tetroxide (OsO4) containing 
1% potassium ferricyanide (K3Fe(CN)6) for 1 hour at room temperature. The tissue was washed 
three times for fifteen minutes in PBS at room temperature and then dehydrated in a series of 
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alcohol/PBS washes for fifteen minutes each: 30% EtOH, 50% EtOH, 70% EtOH, 90% EtOH, 
and three times in 100% EtOH. The samples were further dehydrated with two total ten minute 
incubations in propylene oxide, and then infiltrated for one hour in a 1:1 propylene 
oxide:Polybed 812 epoxy resin (Polysciences, Warrington, PA).  Next, the tissue was infiltrated 
with pure epon four times for 1 hour each. The tissue was then embedded in pure epon at 37
o
C 
for 24 hours and subsequently cured at 60
o
C for 48 hours. The tissue was sectioned into ultrathin 
(60 nm) sections and collected on 200 mesh copper grids. Grids were hand stained with 2% 
uranyl acetate in 50% methanol for ten minutes and 1% lead citrate for seven minutes. Digital 
transmission electron microscopy (TEM) images were taken with JEOL JEM-1011 Transmission 
Electron Microscope (Peabody, MA) at 80.0 kV. Quantitative analysis of junctions was done 
with MetaMorph Software (Molecular Devices, Sunnyvale, CA) at the CBI. Average distances 
from n > 3 measurements at the same magnification were compared for statistical significance by 
Student‟s t-test. 
7.10 PROLIFERATION STUDIES 
7.10.1 Ki-67 staining 
Ki-67 staining was performed similarly to the methods listed in the immunohistochemistry 
section (7.8.3) using a Ki-67 antibody (Dako, Carpinteria, CA). 
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7.10.2 [3H]Thymidine incorporation 
DNA synthesis was measured to assess proliferation of cells as previously described [170]. 
Briefly, 24 hours after siRNA transfection in Hep3B cells [3H]thymidine (2.5 mCi/ml) was 
added to culture media. The cells were cultured for [3H]thymidine incorporation for an 
additional 24 to 48 hours. The cells were then washed with 5% ice-cold TCA and lysed with 0.33 
M NaOH. Aliquots diluted in scintillation fluid were used to determine [3H]thymidine 
incorporation on a Beckman Scintillation counter (Brea, CA). Average counts per minute (CPM) 
from triplicate experiments were compared for statistical significance by Student‟s t-test. 
7.11 WNT SIGNALING STUDIES 
7.11.1 TOPflash luciferase assay 
This reporter system has been successfully used to detect both - and -catenin TCF-dependent 
Wnt signaling [122, 127]. Luciferase assays were performed using Dual Luciferase Reporter 
Assay System (Promega, Madison, WI). Average relative light units (RLU) from triplicate 
experiments were compared for statistical significance by Student‟s t-test. Constructs used for 
the study are described in 7.4.4. 
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7.12 CELL-CELL ADHESION STUDIES 
7.12.1 Scratch-wound assay 
Wound-healing assays were performed as previously described [214]. Briefly, cells were grown 
as a confluent monolayer, transfected for 24 hours, and then a wound was made using a p10 
pipette tip. During the assay cells were cultured in 0.5% EMEM to decrease the influence of cell 
proliferation. Cells were imaged periodically for 24 additional hours until the wounds fronts 
began to merge. The wounds were imaged at four different locations for each time point using 
phase-contrast filters at 5x magnification on an Axioskop 40 (Zeiss, Thornwood, NY) inverted 
brightfield microscope and the cell-free area of the scratches was quantified at each time point 
using ImageJ software (National Institutes of Health, Bethesda, MD). Percentage of wound 
closure from triplicate experiments was compared for statistical significance by Student‟s t-test. 
7.12.2 Centrifugal assay for cell adhesion 
Centrifugal Assay for cell adhesion (CAFCA) was performed as previously described [214] (See 
Figure 24). Briefly, transfected cells were pre-labeled with CellTracker Green CMFDA (Life 
Technologies, Grand Island, NY) for fifteen minutes at 37
o
C, then non‐enzymatically dissociated 
from the monolayers using a 1:200 dilution of 500 mM EGTA and 500 mM EDTA in calcium 
and magnesium-free HBSS. The cells were resuspended in EMEM supplemented with 10% FBS 
and replated on an unlabeled confluent monolayer of untransfected cells cultured on collagen-
coated plates. After thirty minutes the wells were washed once with PBS to removed cells which 
did not attach, and fluorescence intensity of labeled cells was quantified using a plate 
 113 
fluorometer at 495/515 nm. The inverted plate was centrifuged at 375g in air-tight chamber filled 
with warm culture media for ten minutes. The cells were washed with PBS and the fluorescence 
intensity of the remaining labeled cells was measured. A value of 100% attachment was assigned 
to the fluorescent measurements recorded for each well prior to centrifuging the plate, and the 
experimental data was expressed as a percentage of cells lost versus the initial 495/515 nm 
reading. Percentage of cells lost from triplicate experiments were compared for statistical 
significance by Student‟s t-test. 
 
 
 
Figure 24. Schematic of Centrifugal Assay for Cell Adhesion (CAFCA). Adapted from McClay & Hertzler, 2001 
[215]. 
7.12.3 Hanging-drop assay 
Hanging-drop assay was performed in a similar way as described previously [113]. For this assay 
treated cells were removed from their monolayer using 0.25% Trypsin-EDTA and counted. The 
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cells were resuspended in 2% EMEM (to decrease the influence of cell proliferation) at a 
concentration of 2.5 x 10
5
 cells/ml, and 20 l drops containing 5000 cells/drop were pipetted 
onto the inner surface of a 10cm
2
 dish lid.  The bottom of the petri dish was filled with 8 ml PBS 
to prevent evaporation of the drops. The lid was placed back on the dish so that the drops of cells 
were hanging from the lid, and the cells were incubated for 20 hours at 37
o
C in a humidified 5% 
carbon dioxide atmosphere. Some drops were pipetted up and down twenty times to assess 
dissociation of cell colonies as a measurement of cadherin-mediated cell adhesion activity. 
Coverslips were placed over the drops, and images were taken using phase-contrast filters at 5x 
magnification on an Axioskop 40 (Zeiss, Thornwood, NY) inverted brightfield microscope. 
Experiments were performed in triplicate. 
7.13 QUANTIFICATION AND STATISTICAL ANALYSIS 
Student‟s t-test was performed using Microsoft Excel 2010 (Microsoft, Redmond, WA) to assess 
statistical significance for a minimum of three different data points per experiment. Unless 
otherwise noted, significance was measured relative to WT or siNegative treatments. A p value 
of less than 0.01 was considered to be significant, unless otherwise noted. Bar graphs were made 
for each data set, and representative data are presented with standard deviations (SD) of the mean 
indicated with error bars. 
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8.0  CONCLUSIONS 
8.1 TARGETING β-CATENIN FOR HCC 
We know that targeting of -catenin for hepatocellular carcinoma (HCC) and for other 
pathologies with aberrant Wnt/-catenin signaling is inevitable. But is -catenin a viable 
therapeutic target? Often overlooked are the dual roles of -catenin in not only Wnt signaling 
but also in cell-cell adhesions at the adherens junctions (AJs). Will anti--catenin therapies 
negatively impact the cell adhesions as well, possibly affecting the outcome of the treatment by 
inadvertently increasing invasion and metastasis of the tumor cells? We performed the studies 
presented here in order to address these questions. Here we identified -catenin increase which 
compensates for -catenin suppression/loss at the AJs in the liver.  Additional studies allowed us 
to make the following important conclusions: 1) -catenin is unable to compensate for -catenin 
in Wnt signaling; 2) -catenin is able to compensate fully for -catenin at the adherens junctions; 
3) the impact of -catenin loss and resulting -catenin increase on the other cell-cell adhesions is 
minimal; and 4) simultaneous loss of - and -catenin is detrimental to cell-cell adhesions. Thus, 
we conclude that -catenin appears to be a druggable target for the treatment of HCC. 
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8.1.1 γ-Catenin is unable to compensate for β-catenin in Wnt signaling 
Changes in -catenin expression in HCC samples are most often linked to aberrant Wnt 
signaling. Reducing -catenin within a cell would in turn decrease the amount of -catenin 
available to participate in Wnt signaling, affecting cancer cell proliferation and growth. Thus, 
anti--catenin therapies have been developed. The efficacy of these drugs is most often exhibited 
as a decrease in TCF-dependent Wnt signaling and/or a decrease in -catenin target gene levels. 
However, the impact on AJs is rarely addressed. Here we show using conditional KO mice and 
also in vitro siRNA and ASO treatments that when -catenin protein levels are decreased in 
hepatocytes or HCC cells, there is an increase in -catenin levels. The increase in -catenin levels 
is concentrated at the AJs, where it takes the place of -catenin in bridging the connection of E-
cadherin to the actin cytoskeleton. Additionally, the increase in -catenin does not appear to be 
oncogenic in the context of -catenin loss. Yet this increase in -catenin is unable to rescue the 
function of -catenin as a component of Wnt signaling both in vivo and in vitro. Thus, in the 
liver it appears that -catenin can take on the responsibility at the AJ, but not in the Wnt 
signaling. This data helps support the hypothesis that -catenin is unable to compensate for every 
-catenin-dependent role in the cell. However, the differential signaling capacities of - and -
catenin in liver and HCC cells could be exploited anti--catenin therapies. 
8.1.2 γ-Catenin is able to compensate fully for β-catenin at the adherens junctions 
The loss of -catenin in the in vivo and in vitro systems presented as a very mild phenotype with 
no obvious adhesive defects. As mentioned in 8.1.1, -catenin increase with -catenin loss was 
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focused to the AJs, where it was able to take the place of -catenin in linking E-cadherin to the 
actin cytoskeleton. When we tested the strength of the AJs, formed by -catenin/E-cadherin 
(steady state junctions) or -catenin/E-cadherin (after -catenin loss), we were unable to detect 
any differences between these junctions. We did not detect a decrease in overall AJ numbers 
with -catenin loss either. Additionally, there were no changes in migration, heterotypic cell-cell 
adhesion strength, or homotypic cell-cell adhesion strength of the altered AJs. Taken together, 
the data presented here indicates that -catenin is dispensable for cell-cell junctions – as long as 
-catenin is available. 
8.1.3 Simultaneous loss of β- and γ-catenin is detrimental to HCC cell-cell adhesion 
The cell-cell junctions of the HCC cells were only negatively impacted when both - and -
catenins were decreased at the same. It is likely that the effects of the loss of both catenins affect 
not only the AJs, but other junctions. We did see a decrease in E-cadherin with dKD of these 
proteins, suggesting a decrease in overall AJ number. Additionally, decreases in E-cadherin 
levels might also indicate an increase in oncogenic potential and epithelial to mesenchymal 
transition of these cells [90, 216]. In the instance of double catenin loss, we observed a 
significant increase in the migratory potential of the HCC cells and a decrease in both 
heterotypic and homotypic cell-cell adhesion strength. This data indicated that HCC cells 
without both catenins might have a poor prognosis via increase in poorly differentiated HCCs 
and an increase in the migration of the cancer to other organs. Thus, when anti--catenin 
therapies are employed to treat HCC in patients, the redundancies of - and -catenin should be 
recognized in order to make sure the levels of these two proteins are not affected simultaneously. 
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8.1.4 The impact of β-catenin loss and concomitant -catenin increase on other cell-cell 
adhesions is minimal 
The loss of -catenin prompted changes in other cell-cell adhesions as well; however, these 
changes also presented as only mild phenotypes. TJ changes with the loss of -catenin appeared 
to still support a functional blood-bile barrier. Desmosomal changes were expected with -
catenin loss since -catenin is an important desmosomal protein. However, there were no 
noticeable changes in the desmosomes. Increases in -catenin protein levels were not due to 
changes in JUP gene expression, but likely due to an increase in serine- and threonine 
phosphorylation-dependent stabilization. This observation indicates that the levels of -catenin 
are independently regulated at AJs and desmosomes. Thus, -catenin is not only dispensable for 
cell-cell adhesions, but the change in -catenin levels are well tolerated by other junctions in the 
hepatocytes, successfully preserving the integrity of the liver. 
8.1.5 β-Catenin is a druggable target for the treatment HCC 
Taken together, the data presented confirms that -catenin is a viable target for the treatment of 
HCC.  Targeting -catenin at a protein level induces compensatory changes in cell-cell adhesions 
to preserve the integrity of the liver while simultaneously reducing the influence of -catenin-
driven Wnt singling. A lack of -catenin is endured by the liver and does not appear to lead to 
specific pathologies; therefore, we anticipate that acute -catenin targeting in HCC will also be 
successful in reducing aberrant Wnt signaling without unintended consequences on liver 
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homeostasis. As a result, it appears that anti--catenin treatments will be well tolerated because 
of the catenin redundancies built into the physiology of epithelial cells. 
 Currently, there are anti--catenin therapies are in preclinical trials. There are two broad 
classes of -catenin inhibitors: 1) ones which block the nuclear -catenin without impacting the 
total levels of -catenin (such as ICG-001 and Pegylated-Interferon-2a) [12, 13] (Figure 18E); 
and 2) inhibitors that suppress -catenin gene and/or protein expression such as siRNA, ASO or 
other indirectly acting agents [11, 59, 196-198] (Figure 18D). The data presented here indicates 
that the inhibitors that suppress -catenin gene and/or protein expression will in fact be 
successful in the clinic; however, the anti--catenin drugs which block the nuclear -catenin 
without impacting the total levels of -catenin maybe closer to use in HCC patients, as a number 
of these drugs are already used for the treatment of other human diseases.  Based on previous 
studies done with ICG-001, there appears to be no detrimental side-effects of this treatment [13], 
leading us to believe that the treatment with ICG-001 most likely does not mimic a dKD, 
especially since the levels of -catenin and -catenin are relatively unchanged as compared to 
their respective controls (Figure 18E). It is possible that a combination of targeted 
transcriptional and translational anti--catenin treatments would be a viable therapeutic option 
for HCC in the future since both appear to have distinct anti--catenin effects. Though the 
druggability of -catenin in HCC and other diseases appears to be ideal, realistically, the 
introduction of siRNA or ASO may prove difficult and not as specific as ICG-001 because of the 
relative stabilities and molecular properties of these two different types of drugs. Therefore 
refining a physiologically stable ASO or siRNA to -catenin which could be delivered in a 
targeted/liver-specific way would be an important step in the successful fruition of anti--catenin 
drugs for treating HCC. 
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8.2 CATENIN SENSING MECHANISM 
In addition to the work presented on -catenin as a druggable target, we also gained insight into 
the regulation of - and -catenin within biological systems which has led us to hypothesize the 
existence of a catenin sensing mechanism within the cell that is regulated in part by PKA. PKA 
is known to phosphorylate -catenin at Ser552 and Ser675 which leads to Wnt- and GSK3-
independent, but TCF-dependent, -catenin signaling [20]. We show here that PKA is involved 
in the serine and threonine phosphorylation and subsequent stabilization of -catenin. We think 
that PKA has the ability to sense the levels of catenins available in the cytosol and negotiate the 
functions of - and -catenins in Wnt signaling at the AJs (Figure 25). In this way, under basal 
conditions PKA will help -catenin maintain normal hepatocyte homeostasis by sustaining 
appropriate amounts of -catenin-dependent Wnt signaling. However, in the absence of -
catenin the PKA signals are transduced by -catenin, inducing its stabilization and AJ 
localization. In this way not only are the AJs maintained, but if there is residual -catenin stored 
in the cell membrane compartment, it could be displaced by -catenin and allowed to participate 
in Wnt signaling to again maintain homeostatic levels of -catenin target genes. By conclusively 
identifying the PKA-dependent mechanism that regulates the interplay between - and -catenin 
we would gain further insight into just how closely these redundant catenins are regulated, and 
how this impacts normal cell biology.  
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Figure 25. Catenin sensing mechanism via PKA. (A) Under basal conditions in the liver PKA helps -catenin 
maintain normal hepatocyte homeostasis by sustaining appropriate amounts of -catenin-dependent signaling. (B) 
At low levels or in the absence of -catenin the PKA signals are transduced by -catenin, inducing its stabilization  
(* indicates ser/thr phosphorylation). 
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9.0  FUTURE DIRECTIONS 
There were some observations made within the scope of research presented here that will require 
further scrutiny. 
9.1 DETERMINE ROLE OF PLAKOPHILIN-3 INCREASE WITH β-CATENIN 
LOSS 
In Chapter 3 we observed a change in the desmosomal protein Pkp3 with -catenin knockout in 
vivo. We thought that this might be the mechanism by with -catenin could be stabilized within 
the cytoplasm, since recent work by others have shown that Pkp3 binds -catenin and E-cadherin 
within the cytoplasm in order to help with the assembly of desmosomes [108]. Attempts to 
address this theory in vivo using the KO mice indicated that there were no changes in Pkp3/-
catenin/E-cadherin complex levels or overall desmosomal structure as compared with WT mice.  
However, the change may be temporal and a careful in vitro time course may be more 
conclusive. It would be helpful to manipulate Pkp3 levels in conjunction with -catenin to more 
directly determine if Pkp3 complex with -catenin is responsible is responsible for the reciprocal 
stabilization of-catenin and possibly contributes to the cadherin-based adhesions. 
 123 
9.2 ADDITIONAL CHARACTERIZATION OF TJ CHANGES WITH β-CATENIN 
LOSS 
Additionally, there were changes in TJ proteins observed in the KO mice. As the possibility of 
anti--catenin therapies for HCC come closer to fruition, it will be imperative to better 
understand how -catenin might impact the paracellular seal created by the TJs in the liver. The 
leakiness of the junctions is very important to overall liver health, as compromised TJs can lead 
to cholestasis [66]. Functional data indicated that the KO hepatocyte TJs were not leakier than 
the WT TJs [164]; however, the state of the TJs was still not equivalent. We theorized that the 
switching of JAM or claudin isoforms at the TJs may have contributed to the leakiness of the 
junctions. However, these hypothesizes should be confirmed with co-precipitation and imaging 
studies of these TJ components.  
9.3 IN DEPTH ANALYSIS OF SERINE/THREONINE PHOSPHORYLATION-
DEPENDENT STABILIZATION OF γ-CATENIN 
Though significant strides were made in elucidating the mechanisms which controls the 
upregulation of -catenin after β-catenin loss or knockdown, further work needs to clarify the 
reciprocal relationship between these catenins in order to highlight the differences or similarities 
in β- and γ-catenin regulation which may be important for future HCC therapies. Initially, it is 
critical that we identify the specific residues on -catenin which are responsible for its 
stabilization. A few groups, including our, have indicated that it is serine/threonine 
phosphorylation which is dictating -catenin‟s stabilization. Importantly, we describe here in 
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Chapter 6 that PKA may be the serine/threonine kinase responsible for the stabilization of -
catenin. Once key serine/threonine residues are identified on -catenin, we can then use site-
directed mutagenesis in order to manipulate theses residues and fully understand the impact of -
catenin stabilization on cell physiology. This knowledge will not only be important for the 
overall characterization of -catenin in biological systems, but will be useful when considering 
anti--catenin therapies. In Chapter 5 we showed that it is critical that at least one of these 
catenins is maintained in order to keep the cell-cell adhesions functioning normally. If anti--
catenin therapies are used for the treatment of cancer, we would want to make sure that those 
mechanisms which lead to the stabilization of -catenin are spared.  
9.4 WILL ALL β-CATENIN INHIBITORS HAVE AN IMPACT ON AJS? 
We also observed in Chapter 5 that it was the overall protein levels of - and -catenin which 
were driving this reciprocal relationship. When we used ICG-001 to block the transactivating 
potential of -catenin, we did not see a decrease in -catenin protein levels or a significant 
change in -catenin levels, though we did see a decrease in -catenin target gene expression as 
expected. Whether drugs like ICG-001 impact the functionality of the AJs is still unknown. 
Therefore it will be critical to perform follow-up studies to determine how ICG-001 will be 
tolerated by the AJs, since this compound does not appear to trigger the catenin sensing 
mechanism within the cell. 
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9.5 STUDY γ-CATENIN’S RESPONSIBILITIES IN LIVER PATHOBIOLOGY 
As mentioned throughout, more work needs to be done in order to understand the importance of 
-catenin, and also desmosomes, to liver biology and pathobiology. We have begun to address 
this topic by creating a liver-specific -catenin knockout mouse (KO) using the Albumin-driven 
Cre-LoxP system. We plan on characterizing this mouse before and after challenges such as 
partial hepatectomy, hepatocyte injury, and biliary injury. In this way we will not only be able to 
address the importance of-catenin to overall liver biology, but also the significance of the 
desmosomes, since research has shown that -catenin is critical for the formation of desmosomes 
[70, 108]. Although acute loss of -catenin in HCC cells does not appear to negatively impact 
cell-cell adhesion (Figure 21), we anticipate that the adhesive phenotype associated with the loss 
of -catenin in hepatocytes might be more severe than that observed in the KO mice since -
catenin has also been implicated in AJ formation [70, 108]. Additionally, the KO model will be 
able to help us address the role of -catenin and/or desmosomes in HCC. There is conflicting 
data on whether the presences of -catenin in HCC is correlated with a better or worse patient 
prognosis [157-159].  It is possible that if -catenin is critical in HCC, the absence of -catenin 
from hepatocytes would result in a spontaneous appearance of cancer in these mice. However, if 
there is no spontaneous cancer formation in these -catenin-null livers, we would be able to 
induce carcinogenesis with DEN or DDC. In this way we could also assess how -catenin levels 
impact the outcome of the HCC.  
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9.6 HOW DOES γ-CATENIN DECREASE CAUSE β-CATENIN ACTIVATION? 
We observed in Chapter 5 that when -catenin was knocked down in HCC cells there was an 
increase in -catenin protein levels and also Wnt reporter activity. More studies on the 
mechanisms regulating this reciprocal -catenin increase will be necessary. It is unclear at this 
point whether this increase is initially governed by changes in gene expression or -catenin 
stabilization. We can begin to address the regulation of this event in vitro by manipulating -
catenin levels and looking at CTNNB1 gene expression and also at the phosphorylation status of 
known -catenin stabilizing residues. Additionally, it is possible that this observation of -
catenin increase with -catenin decrease may have been specific to HCC. Therefore, it would be 
critical to also expand upon these studies in vivo using the KO mice. Initially we would want to 
look at overall -catenin levels to determine whether they are increased with a chronic loss of -
catenin. If so, we could investigate whether -catenin has increased localization at the AJs. 
Additionally, we could stain these livers for -catenin targets cyclinD1 and GS in order to 
determine if there is an increase in Wnt/-catenin signaling as a result of the presumed -catenin 
increase in vivo. Thus, we would be able to determine whether the increase in activated -catenin 
with siRNA to -catenin was only a result of acute loss of-catenin in HCC cells, or whether this 
is a universal observation in liver biology. 
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9.7 CONCLUSIVELY ADDRESS β- AND γ-CATENIN REDUNDANCIES IN THE 
LIVER 
Lastly, to fully understand the physiological impacts of the interplay of - and -catenin within 
the liver, along with the importance of a catenin sensing mechanism, we have also started 
generating a liver-specific - and -catenin double knockout mouse (KO) using the Albumin-
driven Cre-LoxP system. If these mice are viable, we do anticipate a very severe phenotype, 
especially after challenges as a result of compromised AJs and desmosomes. To our surprise, a 
viable double knockout of - and -catenin was recently generated in -myosin heavy chain-
expressing ventricular cardiomyocytes [190]. However, there are a number of differences 
between the cardiomyocyte model and the KO we are proposing to use. Firstly, the 
cardiomyocyte double knockout mouse used tamoxifen-inducible knockout. This system 
provides only an acute change in - and -catenin levels; however, the inducible knockout could 
be helpful if the - and -catenin double knockout is embryonic lethal. Additionally, we propose 
to knock out -catenin from a different tissue type. It is important to note that cardiomyocytes 
only make up 56% of the murine heart [217], while hepatocytes make up 65% of liver cells (but 
90% of the liver mass) [218]; therefore, the double knockout in hepatocytes will most likely have 
a greater impact on the affected organ. Taken together, the results presented in this work along 
with additional experiments proposed in this chapter will help to paint a clearer picture of not 
only the role of -catenin in liver biology and pathobiology, but will also help us better 
understand interplay of these redundant catenins. 
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APPENDIX A 
ANTIBODIES 
Table 5. Antibodies used for WB, IP, IF, and IHC. 
Protein 
Antibody 
Species 
Size 
(kDa) 
WB 
Dilute 
IP 
Dilute 
IF/ 
IHC 
Dilute 
IF Fixation; 
Permeablize 
Company 
Product 
Number 
A6 Rat - - - 1:100 Acetone 
Gift from 
Valentina 
Factor (NIH) 
- 
-Catenin Rabbit 100 1:500 - - - BD 610193 
-Catenin Rabbit - - 1:50 - - Abcam ab51032 
-
Fetoprotein 
Mouse - - - 1:200 Acetone Santa Cruz sc-51506 
-Actin Mouse 42 1:2500 - - - Millipore MAB1501 
-Catenin Mouse 92 1:1000 - - - BD 610154 
-Catenin Rabbit - - - 1:150 
2% PFA; 
Triton X-100 
Santa Cruz sc-7199 
-Catenin Goat - - 1:50 - - Santa Cruz sc-1496 AC 
Cd133 Rabbit - - - 1:200 2% PFA Abcam ab16578 
Claudin-1 Mouse 22 1:200 - - - 
Life 
Technologies 
374900 
Claudin-2 Mouse 22-23 1:250 - - - 
Life 
Technologies 
325600 
Claudin-3 Rabbit 22 1:250 - - - 
Life 
Technologies 
341700 
 129 
Claudin-4 Mouse 22 1:250 - - - 
Life 
Technologies 
329400 
CyclinD1 Mouse 37 1:200 - - - Santa Cruz sc-20044 
Dsc2 Goat 110 1:200 - - - Santa Cruz sc-34311 
Dsg1 Rabbit 
150/ 
160 
1:200 - - - Santa Cruz sc-20114 
Dsg2 Rabbit 59-150 1:200 - - - Santa Cruz sc-20115 
Dsg3 Goat 
108/130/
100/ 
80/75/55 
1:200 - - - Santa Cruz sc-14867 
Dsg4 Goat 99/115 1:200 - - - Santa Cruz sc-28069 
DP I/II Rabbit 
(I) 210; 
(II) 250 
1:200 - - - Santa Cruz sc-33555 
E-cadherin Rabbit 120 1:200 1:50 1:200 
2% PFA; 
Triton X-100 
Santa Cruz sc-7870 
E-cadherin Mouse 120 1:1000 - 1:200 Acetone BD 610182 
E-cadherin Rabbit 
135/ 
120 
1:1000 1:50 1:50 
2% PFA; 
Triton X-100 
Cell 
Signaling 
4065 
Ep-CAM Goat - - - 1:50 
2% PFA; 
Triton X-100 
Santa Cruz sc-23788 
-Catenin Rabbit 80-87 1:1000 1:100 1:50 
2% PFA; 
Triton X-100 
Cell 
Signaling 
2309 
-Catenin Goat 80-87 1:200 - - - Santa Cruz sc-30997 
-Catenin Goat 80-87 1:200 - - - Santa Cruz sc-30996 
Glutamine 
Synthetase 
Rabbit 49 1:200 - - - Santa Cruz sc-9067 
GAPDH Rabbit 37 1:1000 - - - Santa Cruz sc-25778 
HNF4 Rabbit 54 1:200 - - - Santa Cruz sc-8987 
HNF4 Goat 40/54 1:200 - - - Santa Cruz sc-6556 
JAM-A Rabbit 35 1:200 - - - Santa Cruz sc-25629 
Ki-67 Rabbit - - - 1:200 - Dako NM-SP6 
LGR5 Goat - - - 1:200 Acetone Santa Cruz sc-68580 
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Occludin Rabbit 65-82 1:200 - - - Santa Cruz sc-5562 
p-Serine Mouse - 1:150 - - - Santa Cruz sc-81514 
p-
Threonine 
Mouse - 1:150 - - - Santa Cruz sc-5267 
p-Tyrosine Rabbit - 1:150 - - - Santa Cruz sc-18182 
Pkp2 Goat 100 1:200 - - - Santa Cruz sc-18977 
Pkp3 Mouse 87 1:200 - - - Santa Cruz sc-166655 
Pkp3 Rabbit 87 1:200 - - - Abcam ab109441 
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APPENDIX B 
ABBREVIATIONS 
ADP: Atypical ductular proliferation 
AFP: -Fetoprotein 
AJ: Adherens junctions 
Alb: Albumin 
ALT: Alanine aminotransferase 
APC: Adenomatous polyposis coli 
Arm: Armadillo domains/family 
ARVC: Arrhythmogenic right ventricular cardiomyopathy 
ASO: Antisense oligonucleotides 
AST: Aspartate aminotransferase  
KO: Liver-specific -catenin conditional knockout 
KO: Liver-specific - and -catenin conditional knockout 
TrCP: -Transducin repeat-containing protein 
CAFCA: Centrifugal assay for cell adhesion 
CAL: Cytoskeletal-associated lysates 
CBP: Cyclic AMP response element-binding protein 
CK1: Casein kinase Iα 
CaMKII: Calcium/Calmodulin-dependent kinase II 
Cox: Cyclooxygenase 
CPM: Counts per minute 
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Cre: Cre-recombinase 
CTNNB1: Human -catenin gene 
Ctnnb1: Mouse -catenin gene 
Cx: Connexon 
DDC: 3,5-diethoxycarbonyl-1,4-dihydrocollidine 
DEN: N-diethylnitrosamine 
dKD: Double knockdown 
Dkk: Dickkopf 
DP: Desmoplakin 
Dsc: Desmocollin 
Dsg: Desmoglein  
EGF: Epidermal growth factor 
EMEM: Eagle‟s minimal essential medium 
FBS: Fetal bovine serum 
FC-40: FITC-conjugated dextran 
KO: Liver-specific -catenin conditional knockout 
GAPDH: Glyceraldehyde 3-phosphate dehydrogenase 
GJ: Gap junction 
GJIC: Gap junctional intercellular communication 
GS: Glutamine synthetase 
GSK3: Glycogen synthase kinase 3 
HCV: Hepatitis C virus 
HCC: Hepatocellular carcinoma 
HGF: Hepatocyte growth factor/scatter factor 
HMG: High mobility group 
HNF4: Hepatocyte nuclear factor 4  
I-fraction: Triton X-100 insoluble CAL fraction 
IF: Immunofluorescence; Intermediate filament  
IHC: Immunohistochemistry 
IP: Immunoprecipitation 
IFN: Interferon 
 133 
JAM: Junctional adhesion molecule 
JUP: Human -catenin/plakoglobin gene 
Jup: Mouse -catenin/plakoglobin gene 
KD: Knockdown 
kDa: Kilodalton 
KO: Liver-specific -catenin conditional knockout; knockout 
LEF: Lymphocyte enhancer factor 
LOH: Loss of heterozygosity 
LRP: Lipoprotein receptor related protein 
MCD: Methionine- and choline-deficient 
NC: No change 
NSAID: Nonsteroidal anti-inflammatory drugs 
NT: No treatment 
OA: Okadaic acid 
PCP: Planar cell polarity 
Peg-IFN: Pegylated-Interferon-2a 
PBS: phosphate-buffered saline 
PCR: Polymerase chain reaction 
PEST: Proline (P), glutamate (E), serine (S), and threonine (T) domain 
PKA: Protein kinase A 
PKC: Protein kinase C 
PKG: Protein kinase G 
Pkp: Plakophilin 
PVDF: Polyvinylidene difluoride 
R-Etodolac: 1,8-diethyl-1,3,4,9-tetrahydropyrano-[3,4-b] indole-1-acetic acid 
RIPA: Radioimmunoprecipitation assay 
RLU: Relative light units 
S-fraction: Triton X-100 soluble CAL fraction 
SD: Standard deviation 
SEM: Standard error of the mean 
Ser: Serine 
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si-catenin: sKD of -catenin with siRNA 
si+-catenin: dKD of -catenin & -catenin with siRNA 
si-catenin: sKD of -catenin with siRNA 
sKD: Single knockdown 
siNegative: Negative control siRNA 
siRNA: Small interfering RNA 
TCF: T-cell factor 
TEM: Transmission electron microscopy 
Thr: Threonine  
TJ: Tight junction 
TK: Thymidine kinase 
Tyr: Tyrosine 
WB: Western blot 
WCL: Whole-cell lysates 
WT: Wild-type 
ZO: Zona occuldens 
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APPENDIX C 
OUTLINE OF PUBLISHED WORK 
1) Wickline ED, Awuah PK, Behari J, Ross M, Stolz DB, Monga SPS (2011), Hepatocyte 
γ-catenin compensates for conditionally deleted β-catenin at adherens junctions. Journal 
of Hepatology, 55(6): 1256-1262. (Reference: [91]) 
a. Figure 5A – C & E 
b. Figure 6A & B 
c. Figure 7A & B 
d. Figure 8 
e. Figure 9A & B 
f. Figure 12A & B 
g. Table 1 
2) Thompson MD, Wickline ED, Bowen WB, Lu A, Singh S, Misse A, Monga SP (2011), 
Spontaneous repopulation of β-catenin null livers with β-catenin-positive hepatocytes 
after chronic murine liver injury. Hepatology, 54: 1333–1343. (Reference: [169]) 
a. Figure 13A - D 
b. Figure 14 
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c. Figure 15 
d. Figure 16 
3) Wickline ED, Du Y, Stolz DB, Kahn M, Monga SPS (2013), γ-Catenin at adherens 
junctions: Mechanism and biological implications in hepatocellular cancer after β-catenin 
knockdown. Neoplasia,  In Communication.  
a. Figure 10A & B 
b. Figure 11A – E 
c. Figure 17 
d. Figure 18A – E 
e. Figure 19A – C 
f. Figure 20A & B 
g. Figure 21A – D 
h. Figure 22A – C 
4) Unpublished Data 
a. Figure 5D 
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